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Abstract
Lutein (L) and zeaxanthin (Z) are nutrients that reduce the risk of age-related macular degeneration
(AMD). As micronutrients that selectively accumulate in the retina of the eye, L/Z can protect the macula
from oxidative damage that contributes to AMD. This review will discuss the role of genes as a mediator
between increased intake of dietary L/Z and decreased risk of AMD. Figure 1 outlines a pathway of L/Z
that is subject to genetic influences, from 1) the diet to 2) the bloodstream to 3) the retina of the eye.
First, L/Z are carotenoids that cannot be synthesized de novo and must be consumed from fruits and
vegetables in the diet. Secondly, L/Z are transported by high-density lipoproteins (HDL) in the blood to the
retina. Genetic variants that influence HDL status may impact the amount of L/Z that reaches retinal cells.
Thirdly, L is taken up by retinal cells. Intracellularly, L down-regulates the expression of proinflammatory
genes that contribute to the development of advanced AMD. Overall, L/Z are carotenoids in the diet that
are transported by HDL and affect inflammatory pathways in AMD. The intersection of dietary L/Z, genes,
and AMD will be reviewed using exemplary epidemiological, genome-wide association, and in vitro
studies. The literature will support the integration of personalized nutrition, or dietary recommendations
based on genomic information, into the field of eye care.
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Figure 1. The role of lutein (L) and zeaxanthin (Z) in the nutrigenomics of AMD.

Lutein (L) and zeaxanthin (Z) are nutrients that reduce the risk of age-related macular
degeneration (AMD). As micronutrients that selectively accumulate in the retina of the eye, L/Z
can protect the macula from oxidative damage that contributes to AMD. This review will discuss
the role of genes as a mediator between increased intake of dietary L/Z and decreased risk of
AMD. Figure 1 outlines a pathway of L/Z that is subject to genetic influences, from 1) the diet to
2) the bloodstream to 3) the retina of the eye. First, L/Z are carotenoids that cannot be synthesized
de novo and must be consumed from fruits and vegetables in the diet. Secondly, L/Z are
transported by high-density lipoproteins (HDL) in the blood to the retina. Genetic variants that
influence HDL status may impact the amount of L/Z that reaches retinal cells. Thirdly, L is taken
up by retinal cells. Intracellularly, L down-regulates the expression of proinflammatory genes that
contribute to the development of advanced AMD. Overall, L/Z are carotenoids in the diet that are
transported by HDL and affect inflammatory pathways in AMD. The intersection of dietary L/Z,
genes, and AMD will be reviewed using exemplary epidemiological, genome-wide association,
and in vitro studies. The literature will support the integration of personalized nutrition, or dietary
recommendations based on genomic information, into the field of eye care.
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Literature Review of Nutrigenomics of Age-Related Macular Degeneration
Chapter 1. Introduction
1.1 Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease that causes irreversible loss
of central vision.1 In the developed world, AMD is the leading cause of blindness among people
of European ancestry aged 65 or older. AMD is particularly concerning to the healthcare system,
given that its prevalence increases sharply after age 80.2 As the aging population of the US
increases, the impact of AMD will also increase. In the United States alone, an estimated 3
million people will have AMD by the year 2020.3 Worldwide, an estimated 288 million people
will have AMD by the year 2040.4 For those affected, AMD has a profound effect on quality of
life. Patients with vision loss from AMD have reported diagnoses of clinical depression and
significant impairment in their abilities to participate in valued activities.3 The burden of AMD on
patients demands more effective strategies to prevent both the onset and progression of AMD. On
top of AMD’s devastating health effects on quality of life, the disease also has a costly financial
impact on the economy. In 2012, the economic burden of advanced neovascular AMD and
advanced dry AMD on the US gross domestic profit was estimated to be over $40 billion.5 The
projected substantial global impact of AMD calls for a need to discover and implement new eye
care strategies.
Early
AMD

Intermediate
AMD

Advanced
AMD

Neovascular

Dry

Figure 2. Classifications of AMD. There are three main stages of AMD, each progressing in
severity of vision loss.6 Early AMD is the first stage of AMD, intermediate AMD is the second
stage of AMD, and advanced AMD is end stage macular degeneration. There are two types of
advanced AMD: dry and neovascular (wet) AMD.

As its name suggests, AMD is strongly associated with aging, and can be categorized into
temporal stages. Figure 2 shows the three main stages of AMD, each increasing in severity of
vision loss.6 The first stage of AMD is known as early AMD. Early AMD is characterized by the
presence of soft drusen and pigment abnormalities in the retinal epithelium. Drusen are yellow
deposits of waste products found under the retina. Retinal pigment abnormalities consist of either
hyper- or hypo-pigmentation in retinal epithelial cells. Most patients do not experience vision loss
with early AMD. Over time, early AMD may develop into intermediate AMD. Intermediate
AMD is characterized by the presence of larger-sized soft drusen and retinal pigment
abnormalities. Patients may experience some vision loss at this stage. In some cases, intermediate
AMD further develops into advanced AMD. Advanced AMD can be either categorized as dry
AMD or neovascular (wet) AMD. Dry AMD is characterized by atrophy of light-sensitive cells in
the macula. Vision loss due to dry AMD is typically a gradual process occurring over a period of
years. Neovascular AMD is characterized by the abnormal growth of weak blood vessels under
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the retina, which can leak fluid and damage the macula. Vision loss due to neovascular AMD is
typically a rapid process occurring over weeks or months. In clinical studies, AMD status is often
classified by trained graders, using images of the retina that are captured by digital fundus
photography.7
Between the two subtypes of advanced AMD, the dry form is more common than the
neovascular form. However, neovascular AMD is characterized by more rapid and severe vision
loss.8 Due to its serious health implications, this review will primarily focus on the advanced,
neovascular form of AMD. A major challenge of the current healthcare system is the pressure to
meet the demands of long-term vision care in the elderly population. Even though neovascular
AMD is rare, representing approximately 10% of AMD cases,9 its severity calls for the pursuit of
new preventive strategies in order to avoid a large increase in cases of advanced AMD.
One such strategy is personalized nutrition. Given that food is a consistent, readily
available commodity in the developed world, targeting diet has the potential to prevent a large
increase in prevalence of AMD. In applying personalized nutrition to AMD, clinicians use the
unique genomic information of individual patients to make specific dietary recommendations that
correlate with the greatest reduced risk of disease. As genetic testing becomes more accessible,
the future of healthcare lies in personalized nutrition. A solid understanding of how genes may
link diet to AMD is required in order to pinpoint nutrient intake levels that have the greatest
protective effect. The literature presented in this review will show the importance of diet-gene
interactions in the development of advanced AMD. Accordingly, this review will investigate the
associations between advanced AMD, genetic makeup, and two micronutrients consumed in the
diet.
1.2 Introduction to Important Nutrients for AMD
Two micronutrients that are important in AMD are the carotenoids lutein (L) and
zeaxanthin (Z). Notably, humans cannot synthesize carotenoids de novo, and must obtain L/Z
exclusively from the diet.10 With respect to AMD, L/Z are important because they selectively
accumulate in the macula, which is the region of the eye responsible for central vision.11
Generally, higher concentrations of L/Z in the macula result in greater protection against
oxidative damage that contributes to AMD.12 Thus, L/Z are often referred to as dietary macular
carotenoids that have important roles in modulating AMD risk.13
1.3 Carotenoids
Carotenoids are fat-soluble pigments synthesized by a variety of plants, resulting in the
bright colors of fruits and vegetables.14 Structurally, carotenoids are tetraterpenoids that contain a
central hydrocarbon chain of 40 carbons and end groups that are either cyclic or noncyclic.10
Carotenoids can be divided into two major classes: carotenes and xanthophylls. Carotenes are
reddish-orange pigments, chemically characterized by only carbon and hydrogen atoms.
Xanthophylls are yellow pigments, chemically characterized by at least one oxygen atom.
Examples of xanthophylls are the micronutrients lutein (L) and zeaxanthin (Z). Figure 3 depicts
the chemical structures of L and Z.15 Both xanthophylls have a C40H56 central conjugated chain,
and two hydroxyl groups. The presence of hydroxyl groups allow L/Z to have modestly better
aqueous solubility than other carotenoids, which are typically very hydrophobic. Z also contains
an extra conjugated double bond, which may lead Z to have different cellular effects as compared
to L.

2

Importantly, animals and humans cannot synthesize carotenoids de novo.10 All
carotenoids in the human body must come from dietary supply.

Lutein

Zeaxanthin
Figure 3. Adapted from Woodall.15 Structures of the dietary macular carotenoids L and Z.
Carotenoids are characterized by a core system of C 40H56 conjugated polyene backbone chains
(blue). L and Z both contain two hydroxyl groups, at the C-3 and C-3’ positions (green). L
contains a double bond at the 4′, 5′ position (red, above), whereas Z contains a double bond at the
5′, 6′ position (red, below).

1.3.1 Lutein and Zeaxanthin
Lutein (L) and zeaxanthin (Z) are the only dietary carotenoids found in eye tissues that
are critical to vision.16 Therefore, L/Z were chosen for inclusion in this review because they are
known to selectively accumulate in the macula of the eye.11 In the eye, the macula is a 6 mm
region located in the central area of the retina that is responsible for high-acuity vision.17 Given
that L/Z are obtained exclusively from the diet and compose pigment in the macula of the eye,
L/Z are often referred to as dietary macular carotenoids.13
L and Z are fat-soluble micronutrients belonging to the carotenoid family. As previously
discussed, carotenoids are naturally occurring pigments found in almost all colored fruits and
green leafy vegetables.18 Because humans do not synthesize carotenoids, L/Z must be consumed
in the diet from sources such as spinach, peppers, and kiwi.11 Table 1 lists the concentrations of L
and Z in commonly consumed fruits and vegetables. Notably, L is the predominant carotenoid in
most of the listed foods. Green leafy vegetables are generally the richest sources of L. Also of
particular interest is the wide variation of L/Z concentration in different cultivars of corn.19 Thus,
there may be vastly different L/Z contents in different commercial varieties of the same plant.
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Table 1. Adapted from Perry and Fanning.11,19 L and Z concentrations (μg/100 g) in fruits and vegetables.

Lutein (μg/100 g)

Zeaxanthin (μg/100 g)

171
53
24
15
11

0
6
4
0
3

6603
772
490
30
171
62
0

0
0
190
30
12
18
22

Fruits
Kiwi
Grapes, green
Grapes, red
Apple, red delicious with skin
Peach, raw
Vegetables
Spinach, raw
Broccoli, cooked
Corn, Golden Sweet Improved
Corn, White
Lettuce, iceburg
Artichoke heart
Red Pepper

1.4 Age-Related Eye Disease Study (AREDS): A Starting Point for Nutrient-AMD Link
In 2001, the Age-Related Eye Disease Study (AREDS) was one of the first major clinical
studies to suggest a link between micronutrients and AMD.20 As a large, interventional study
conducted from 1992 to 2001, AREDS followed 3,540 participants aged 55 to 80 for an average
of 6.3 years. At baseline, participants had either early AMD in at least one eye, intermediate
AMD in at least one eye, or advanced AMD in one eye. To evaluate the effect of certain
micronutrients on AMD progression, participants were assigned daily dietary supplements. These
supplements were oral tablets that contained high doses of vitamin C, vitamin E, beta carotene,
zinc, and copper. Participants were then examined annually for AMD. The results of AREDS
showed that the combination of vitamins and minerals reduced the risk of progression to
advanced AMD by 25%. Thus, AREDS provided the first evidence of the beneficial effects of
nutritional supplements on advanced AMD. Unfortunately, AREDS was unable to observe any
effects of L and/or Z because these carotenoids were not yet available in formulation at the time
of this study.
Five years after the publication of AREDS, a follow-up study known as Age-Related Eye
Disease Study 2 (AREDS2) was initiated.21 In AREDS2, the effects of L and Z were evaluated to
understand whether these carotenoid pigments could further reduce the risk of AMD progression.
From 2006 to 2012, AREDS2 followed 4,203 participants aged 50 to 85 for an average of 5 years.
At baseline, participants had either intermediate AMD or advanced AMD in one eye.
Interestingly, the results of AREDS2 suggested that adding both L (10 mg) and Z (2 mg) to the
original AREDS formulation only reduced progression to advanced AMD in certain conditions.
Specifically, the beneficial effects of supplemental L/Z were only observed in participants who
originally consumed the lowest amounts of dietary L/Z, as well as in participants who received a
formulation without beta carotene. Thus, AREDS and AREDS2 demonstrated that high doses of
supplemental L/Z had limited beneficial effects against advanced AMD.
In contrast to supplemental intake of L/Z in AREDS2, this review will focus on dietary
intake of L/Z. Normal dietary levels of L/Z are generally much lower than the high dosages tested
in AREDS2. To put the different L/Z contents in perspective, the L dosage in 10 mg of

4

supplemental L is equivalent to that in 1,295 g (approximately 6.4 cups) of cooked broccoli.11
The Z dosage in 2 mg of supplemental Z is equivalent to that in 9,091 g (approximately 45 cups)
of red pepper. Based on the Dietary Guidelines for Americans’s recommendation that nutritional
needs should primarily be met through diet, studies investigating the effects of supplemental L/Z
will be excluded.22 Accordingly, this review will focus on whether consumption of dietary
sources of L/Z can be protective against advanced AMD.
1.5 Genetic Factors of AMD
Notably, genetic effects that may connect L/Z to AMD have not yet been extensively
studied in humans. Potential genetic effects include variations in genotype and gene expression.
Accordingly, this review will compile literature examining both directionalities of nutrient-gene
interactions relating to AMD: 1) gene to nutrient (genotype) and 2) nutrient to gene (gene
expression). Figure 4 shows a simplified pathway by which genotype and gene expression factor
into the application of personalized nutrition to eye disease. In personalized nutrition, the unique
genomic information of individuals can be used to customize dietary recommendations for the
greatest reduced risk of eye disease.

Genotype

Gene
Expression

Nutrients

Eye
Disease

Figure 4. An overview of the application of personalized nutrition to eye disease.

First, from gene to nutrient, an individual’s genotype may impact the body’s response to
L/Z.23 Specific sets of genes direct specific metabolic processes, including the transport of L/Z to
retinal cells, where greater accumulation of L/Z leads to greater protective effects against AMD.
In particular, HDL (high-density lipoprotein) is important due to its role as the primary
lipoprotein transporter of L and Z.24 Given that retinal cells are high in HDL receptors, there is
preferential uptake of L/Z from HDL into the retina. However, different variants in HDL-related
genes may change the efficiency by which L/Z undergo uptake and transport into the retina, thus
modulating the risk of developing AMD.
Secondly, from nutrient to gene, L/Z may regulate the expression of genes that contribute
to AMD. Inside retinal cells, L/Z can decrease the concentration of genes and proteins involved in
AMD pathogenesis. This review will focus on proinflammatory genes and proteins because the
inflammatory response has been implicated as one of many possible pathways involved in AMD
pathogenesis.25 Reactive oxygen species (ROS) have been found to upregulate proinflammatory
pathways in the eye, causing morphological impairments to the RPE.26 Upon initial exposure to
high-energy light, cells in the retinal pigment epithelium (RPE) become damaged.27 Damage to
retinal cells then induces the production of ROS, such as superoxide anion (O2-), hydroxyl radical
(OH•), hydrogen peroxide (H2O2), and singlet oxygen (1O2). In normal cellular metabolism, ROS
are present at low concentrations and have beneficial effects. In conditions of oxidative stress,
ROS are present at high concentrations and have deleterious effects. The highly reactive free
radicals of ROS are known to damage cell structures, DNA, lipids, and proteins.28 The overall
result of ROS accumulation is a chronic inflammatory response that exacerbates retinal damage,
leading to advanced forms of AMD.25 Thus, the modulation of proinflammatory gene expression

5

will be investigated because inflammation may contribute to the development of later stages of
AMD.
Both gene-to-nutrient and nutrient-to-gene interactions will be investigated to get a
holistic understanding of the term “nutrigenomics”. Such interactions between L/Z and genes will
also be discussed in the context of AMD pathogenesis to get a comprehensive understanding of
nutrigenomics leading to the progression of neovascular AMD.
1.6 Goals and Objectives
The overall goal of this review is to demonstrate the effectiveness of personalized
nutrition, specifically dietary L/Z, in preventing development of advanced AMD. To do so, the
interactions between dietary levels of L/Z, genetic variation, and advanced AMD will be
explored. Figure 5 presents a pathway showing how dietary L/Z could accumulate in the retina of
the eye, where a high concentration of L/Z is protective, as well as two points in L/Z’s pathway at
which genetic influences may inhibit development of advanced AMD. First, foods containing L/Z
are consumed in the diet. L/Z are then released from food matrices and absorbed into the
bloodstream. Coupled to HDL carriers in the blood, L/Z can then be transported to the eye. Here,
genetic variants affecting HDL status may increase the efficiency of L/Z uptake into retinal cells.
L/Z that are transported into the retina then selectively accumulate in the macula. Here, L may
down-regulate the expression of inflammatory genes that contribute to AMD pathogenesis.
Overall, dietary L/Z may prevent the development of advanced AMD through genetic effects
related to HDL transport and inflammatory response.
The objectives of this review are twofold: 1) to examine the clinical effects of dietary L/Z
in development of advanced AMD, and 2) to compile current research supporting a role for
genetics as a link between L/Z and advanced AMD.
This review will take the form of a critical discussion that compares and contrasts
different methodologies and arguments. Analyses of exemplary studies, promising research
methods, and differing author opinions will be guided by a thesis arguing for the integration of
personalized nutrition in eye care. To begin, epidemiological studies reporting associations
between dietary L/Z and advanced AMD will be analyzed. Next, the interactions between L/Z
and genetics will be examined from two aspects: genotype and gene expression. Genotype will be
investigated by GWAS studies to understand how genetic variants related to HDL status
influence the efficiency of L/Z transport to the retina, affecting susceptibility of developing
AMD. Gene expression will be investigated by in vitro studies to understand how L may downregulate proinflammatory genes and proteins involved in AMD pathogenesis. Finally, the review
will conclude by highlighting gaps in current research and future directions. Ultimately, this
review will advance the field of eye care by advocating a unique approach to preventing
development of advanced AMD from a personalized nutrition perspective.
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L/Z
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f

a
Macula

c

Foods
Containing
L/Z

b

Retinal Cell
in Macula
RPE and Photoreceptors
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Figure 5. An outline of the nutrigenomics of AMD. Increased levels of lutein (L) and zeaxanthin
(Z) in the retina is protective. Foods containing L/Z are consumed (a) by an individual. L/Z are
absorbed (b) and transported (c) to the eye. L/Z selectively accumulate in the macula (d), which is
the central area of the retina that is damaged when an individual has AMD (e). Based on an
individual’s genotype, genetic variants affecting HDL status may influence the efficiency of L/Z
uptake into retinal pigment epithelium cells (f). Once inside retinal cells, L may down-regulate the
expression of inflammatory genes that contribute to AMD pathogenesis (g).
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Chapter 2. Epidemiological Studies Evaluating the Relationship Between L/Z and AMD
Risk
This review will first focus on human epidemiological studies reporting associations
between dietary L/Z and advanced AMD. The literature as a whole shows that higher levels of
dietary carotenoid intake are associated with a reduced risk for advanced neovascular AMD.
Greater understanding of the extent to which dietary L/Z affects development of advanced AMD
will justify the feasibility of dietary L/Z as a strategy to delay the progression of AMD. Table 2
shows a compilation of the main results from epidemiological studies that will be discussed in
detail in this chapter.
2.1 Dietary L/Z and Advanced AMD
2.1.1 Methodology

A

B

Increasing dietary L/Z intake

Epidemiological studies can be categorized as cross-sectional or prospective. A crosssectional study is one type of epidemiology study that analyzes a population at a single point in
time. The main advantages to cross-sectional studies are that they are less costly and can compare
many different variables at one time to reveal correlations. Conversely, the main disadvantage to
cross-sectional studies is that they cannot establish causal relationships.
A prospective study is another type of epidemiology study that analyzes a population
over an extended time period. The main advantages to prospective studies are that they can be
tailored to collect specific data, and used to provide a timeline between exposure and onset of
disease.29 However, the main limitation to prospective studies is the larger expense incurred over
a long period of time.
5th
quintile
4th
quintile
3rd
quintile
nd

2
quintile
1st
quintile

C

5th
quintile
4th
quintile
3rd
quintile
2nd
quintile
1st
quintile

OR

Interpretation

0.1

90% decreased
AMD risk
60% decreased
AMD risk
20% decreased
AMD risk
10% increased
AMD risk
0% AMD risk

0.4
0.8
1.1
1

Figure 6. Collection and analysis of data in epidemiological studies.

Before comparing epidemiological studies, common methodologies used to collect and
analyze clinical data will be discussed. Figure 6 depicts the general methodology for
epidemiological studies, from A) data collection to B) data organization to C) data analysis. For
data collection, dietary intake levels are commonly measured using food-frequency
questionnaires (FFQs). FFQs are used to collect information on dietary habits by asking
participants to note the type of food consumed, frequency of consumption, and/or portion size
over a set period of time.30 Figure 6A depicts a population that is separated when individuals
report distinct dietary habits on FFQs. Completed FFQs can then be used to generate intake
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scores for various micronutrients, based on standard nutrient values derived from United States
Department of Agriculture (USDA) sources.
For epidemiological studies, FFQs are advantageous because they are a simple way to
collect a large amount of individual data over an extended period of time. Additionally, the
extended duration of data collection allows FFQs to account for wide day-to-day variations in
nutrient intake. On the other hand, FFQs are disadvantageous because they may not accurately
reflect specific types of foods consumed. The limited checklist of foods provided by FFQs will
not completely match the exact types and prepared forms of foods consumed by participants.
Recalling that different cultivars of plants may have vastly different L/Z contents19, the simplified
list of foods on FFQs can lead to under- or over-estimations of nutrient values.
To analyze the relationship between advanced AMD risk and L/Z nutrient levels, the
generated nutrient scores derived from FFQs are typically categorized into tertiles, quartiles, or
quintiles of intake. In other words, participants are split into three, four, or five groups based on
how much L/Z they consume. Figure 6B depicts a population that is divided into five groups,
from lowest L/Z intake (1st quintile) to highest L/Z intake (5th quintile). Odds ratios (ORs) are
then calculated for each level of L/Z intake. Generally, ORs measure the association between an
outcome and exposure.31 For the epidemiological studies included in this review, ORs reveal the
odds of AMD occurring at each level of dietary L/Z intake. Figure 6C depicts the assignment of
ORs to each group. As part of the analysis, either the highest or lowest level of dietary intake is
set as a reference (OR = 1). The other levels of intake are then assigned OR values and compared
to the reference. ORs > 1 indicate higher occurrence of AMD, and ORs < 1 indicate lower
occurrence of AMD. For example, if the lowest dietary intake group is assigned as the reference
(OR = 1), and higher dietary intake groups have OR values < 1, then the result indicates that
increasing L/Z intake correlates with lower occurrence of AMD. In clinical research, ORs are
particularly useful because they are simple measures that indicate what treatment has the best
odds of improving a patient’s condition.
2.1.2 Cross-Sectional Studies
The published literature of relevant cross-sectional clinical studies has been controversial
regarding the role of L/Z in AMD. Despite purported inconsistencies, a review of the data will
reveal that dietary L/Z indeed has a protective role against advanced AMD. Three cross-sectional
studies analyzing three separate populations will be presented. Two studies focused specifically
on neovascular AMD, while one study did not differentiate between forms of advanced AMD.
Prior to AREDS, evidence supporting the protective effect of L/Z on the neovascular
form of advanced AMD was first reported in 1994.32 In a case-control study, Seddon aimed to
evaluate the relationship between advanced AMD and intake of antioxidant nutrients in specific
food items. As a medium-sized study, a total of 876 subjects from the Eye Disease Case-Control
Study (EDCCS) were included. Three hundred fifty-six case subjects aged 55 to 80 who were
diagnosed with advanced AMD were compared to 520 control subjects of the same age range and
geographic areas.
The overall results showed that higher levels of dietary carotenoid intake were associated
with a reduced risk for neovascular AMD. In other words, there was a lower fraction of cases
(with neovascular AMD) within the group consuming the greatest amount of total carotenoids, as
compared to the fraction of cases in the group consuming the least amount of total carotenoids.
Specifically, subjects in the highest quintile of total carotenoid intake (11,548 μg) were estimated
to have a 43% decreased risk of AMD (OR = 0.57), as compared to the lowest quintile group
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which was assigned a reference 0% decreased AMD risk (OR = 1). Notably, when L/Z were
evaluated separately from beta-carotene, the highest quintile of L/Z intake (3455 μg) correlated
with an even greater 57% decreased risk of AMD (OR = 0.43), suggesting that L/Z are the dietary
carotenoids important for protecting against AMD. Similarly, when the effects of beta-carotene
and L/Z were analyzed simultaneously, beta-carotene was only associated with a minor 9%
reduced risk of AMD (OR = 0.91), whereas L/Z were strongly associated with a 56% reduced
risk of AMD (OR = 0.44). The findings clearly indicated an inverse association between high
dietary intake of L/Z and lower incidence of advanced neovascular AMD.
As opposed to the results of Seddon’s case-control study, a cohort study published at the
same time as AREDS reported no association between L/Z and advanced AMD.33 In this 2001
cohort study, Mares-Perlman aimed to determine the relationship between dietary L/Z and
advanced AMD. As a large study, a total of 8,244 participants from the Third National Health and
Nutrition Examination Survey (NHANES III) were included.
The overall results showed that there was no association between dietary L/Z and
advanced AMD in the overall NHANES III sample. However, when subjects were stratified by
age, conflicting results were observed. In the lowest age group of 60-79 years, subjects in the
highest quintile of dietary L/Z intake had a significant 90% reduced risk of advanced AMD (OR
= 0.1). On the other hand, for subjects aged 80 years and older, those in the highest L/Z quintiles
had only a 40% reduced risk of advanced AMD (OR = 0.6). Mares-Perlman’s study concluded
that most of the observed associations between dietary L/Z and advanced AMD were not
significant, which directly contradicts Seddon’s results. However, specific subgroup analysis of
people aged 60-79 years did show a significant protective effect of dietary L/Z on advanced
AMD, which is consistent with Seddon’s results.
The 2001 Mares-Perlman study differed from the 1994 Seddon study in terms of
objective and participants. The sample size of Mares-Perlman’s study was more than 9-fold
greater than that of Seddon’s study, suggesting that the results reported by Mares-Perlman were
more reliable. However, the Mares-Perlman study’s observed lack of association between dietary
L/Z and advanced AMD should not be interpreted as a blanket conclusion. Although the overall
results concluded by Mares-Perlman and Seddon contrasted each other, the specific subgroup
analysis of subjects aged approximately 60-80 years in fact support similar conclusions in both
studies. Seddon’s analysis of 876 subjects aged 55-80 years and Mares-Perlman’s analysis of
3,143 subjects aged 60-79 years supported a 57% and 90% reduced risk of AMD, respectively.
As shown in Figure 7, both studies suggest that increasing L/Z intake in the diet can potentially
protect against advanced forms of AMD, particularly in individuals aged 60-79 years. The
difference in magnitude of effect could possibly be explained by the difference in race
distribution of the participants. While Mares-Perlman included Blacks and Mexican Americans in
their study, Seddon only analyzed White participants. Another possibility explaining variation in
magnitude of effect is that Seddon looked specifically at one form of advanced AMD
(neovascular AMD), while Mares-Perlman did not distinguish between the two forms of
advanced AMD.
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L/Z-containing foods

Eye with advanced AMD

Figure 7. Cross-sectional studies point to an inverse association between dietary L/Z intake and
advanced AMD. Participants aged 60-79 with high L/Z intake had lowest occurrences of advanced
AMD, particularly the neovascular form.

Further support for dietary L/Z’s protective role against advanced AMD was reported by
Snellen in a 2002 small case-control study.34 Similar to Seddon’s case-control study, Snellen
aimed to evaluate the relationship between dietary L/Z intake and the neovascular form of
advanced AMD. A total of 138 subjects from the Netherlands were included in this smaller study.
Seventy-two cases aged 60 years or older who were diagnosed with neovascular AMD were
compared to 66 control patients.
The overall results showed that lower intake of dietary carotenoid intake was associated
with higher occurrence of neovascular AMD. Subjects in the lowest quartile of L/Z intake had
double the prevalence rate of neovascular AMD (OR = 2.4), as compared to the prevalence rate of
patients in the highest quartile of L/Z intake (OR = 1). Thus, Snellen’s results further bolster the
suggested protective effects of L/Z against advanced AMD, and against neovascular AMD in
particular.
It should be noted that Snellen’s methodology of data collection differed from that used
by Seddon and Mares-Perlman. Instead of using FFQs, subjects were verbally interviewed about
their dietary habits and their intakes of fruits and vegetables. The method of using a verbal
interview was advantageous because it removed possible misreading of questions, as patients
with AMD had poor visual acuity and may not have been able to correctly read FFQs. However,
introducing an interviewer into the methodology of data collection could have potentially altered
the subjects’ answers, especially given that interviewers were not blind to the subjects’ disease
statuses. Analysis of L/Z intake levels were also performed slightly differently than either Seddon
or Mares-Perlman. Whereas the previous studies used standard nutrient values derived from the
USDA, Snellen used L/Z values derived from the carotenoid database generated by Mangels in
1993.35 Given that the USDA Nutrient Database is more recent and contains L/Z values for a
greater variety of foods, USDA nutrient values are likely more reliable than nutrient values
derived by Mangels’s original 1993 carotenoid database. Despite differences in data collection,
Snellen’s small-scale study supported the results of Seddon and Mares-Perlman’s large-scale
studies.
2.1.3 Prospective Studies
The published literature of relevant prospective clinical studies have been partly
inconsistent regarding the role of dietary L/Z in AMD. Interestingly, some purported
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contradictory results have been drawn from the same population cohort that was simply followed
over different lengths of time. Given that AMD has distinct early and late stages, understanding
the etiology of advanced AMD also requires understanding of its preceding stages. On the
surface, discussing studies that focus on earlier stages of AMD seems to contradict the purpose of
this review. However, the inclusion of early and intermediate AMD here will help clarify how
high dietary L/Z is associated with less incidences of advanced AMD. As shown in Figure 8A,
there are two phases in the development of advanced AMD at which L/Z could decrease the final
number of advanced AMD cases. That is, does dietary L/Z correlate with lower occurrences of
advanced AMD by preventing the initial occurrence of early AMD, or by preventing the
progression of initial stages of AMD to advanced AMD?
To help answer this question, the four prospective studies presented will represent two
population cohorts followed over different periods of time. One population cohort was examined
for early AMD and advanced AMD, while the other population cohort was analyzed for early
AMD, intermediate AMD, and advanced AMD. Specific analyses both within the same
population cohort and between different cohorts will reveal that dietary L/Z has a protective role
against progression to the advanced stage of AMD.
A

No AMD

Early AMD

Advanced AMD

B

L/Z-containing foods

L/Z-containing foods

Early AMD

Advanced AMD

Figure 8. Prospective studies point to a protective role for dietary L/Z against the progression of
early AMD to advanced AMD. (A) Without dietary L/Z, there is uninhibited onset of early AMD,
and uninhibited progression of early AMD to advanced AMD. (B) With dietary L/Z, L/Z may
delay the progression of early AMD to advanced forms. L/Z may also be weakly protective against
onset of early AMD within a certain range of intake.

The first population discussed here is the Blue Mountains Eye Study (BMES) cohort. In a 5year study, Flood aimed to evaluate the relationship between dietary L/Z intake and incidence of
early AMD.36 From 1992 to 1994, a baseline total of 3654 BMES participants in Australia were
examined. Five years later, from 1997 to 1999, 2335 of the original participants were reexamined.
The overall result showed that there was no association between baseline dietary L/Z
intake and the 5-year incidence of early AMD in the BMES population. Although 192
participants (8.2% of the follow-up sample) were observed to develop early AMD after 5 years,
L/Z intake did not appear to be a protective or risk factor into the 5-year incidence of early AMD.
The lowest and highest L/Z intake quintiles both had ORs of 1.0, indicating that L/Z intake did
not reduce risk of early AMD.
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However, when the BMES participants were followed-up after an additional 5 years, an
inverse association between L/Z intake and AMD was in fact observed. In this follow-up study,
Tan aimed to elucidate the long-term risk of AMD by evaluating the effect of dietary L/Z intake
on both early and advanced AMD.37 As continuation from the BMES study, 1952 participants
(53.4% of the original 3654-person cohort) were reexamined after a total of 10 years.
Analysis of dietary L/Z intake levels was performed differently in Tan’s 2008 study.
Instead of calculating ORs for each L/Z intake level, risk ratios (RRs) were calculated. RRs are
inherently different from ORs in that RRs measure a ratio of probabilities, whereas ORs measure
a ratio of an event to a nonevent.38 RRs should be interpreted as increased risk of disease (RR >
1) or decreased risk of disease (RR < 1) among persons who have been exposed (to a certain level
of dietary L/Z intake), relative to the control group.
Interestingly, the early AMD results from the 10-year BMES seemed to contradict those
of the 5-year BMES. The 10-year BMES showed that above-median L/Z intakes were associated
with reduced risk of early AMD. In contrast, the 5-year study reported no overall association.
However, combining levels of L/Z intake between the 5-year and 10-year studies showed that
although too much or too little L/Z intake has no effect, there may be an optimal range at which
L/Z intake is protective against early AMD. In the 5-year study, there was no difference in OR
between the top L/Z intake quintile (1466 μg) and the bottom L/Z intake quintile (288 μg),
suggesting that the highest and lowest extremes of L/Z intake had no effect on risk of early AMD.
Yet, the third (733 μg) and fourth (967 μg) L/Z intake quintiles did show some reduced risk of
early AMD (OR = 0.8 and OR = 0.7, respectively). Similarly, the 10-year study observed that
daily L/Z intakes of more than 743 μg were associated with some reduced risk of early AMD (RR
= 0.66). As depicted in Figure 8B, the combined results of the 5-year and 10-year BMES studies
indicate that at specific L/Z intake levels between 733 μg and 1466 μg, L/Z may be weakly
protective against onset of early AMD.
The advantage of the 10-year BMES study was its ability to follow the development of
advanced AMD, in addition to early AMD. When participants were tracked for 10 years instead
of 5 years, the highest tertile of L/Z intake (at least 942 μg/day) was associated with reduced risk
of advanced AMD (RR = 0.72). Even more significantly, the highest L/Z intakes were associated
with reduced risk of the neovascular form of advanced AMD (RR = 0.37). The strong association
between dietary L/Z and neovascular AMD observed in the 10-year BMES is consistent with the
results of cross-sectional studies. Moreover, the fact that dietary L/Z intake was more strongly
associated with advanced neovascular AMD (RR = 0.37) than with early AMD (RR = 0.66),
suggests a protective role for dietary L/Z in AMD progression rather than AMD initiation. Figure
8B depicts the effects of dietary L/Z on development of AMD, showing that L/Z may have a
stronger effect on inhibiting progression to advanced AMD than on inhibiting initiation of early
AMD.
Further support for dietary L/Z’s beneficial effect was later reported in a large-scale study
that followed a different population cohort over an even longer duration of time. The second
population discussed here is the combined Nurses' Health Study (NHS) and Health Professionals
Follow-Up Study (HPFS) cohort. In an 18-year cohort study, Cho aimed to assess the effect of
dietary L/Z intake on both early and advanced AMD.39 Thus, the objective of this 18-year
NHS/HPFS study was similar to that of the 10-year BMES study, in terms of evaluating both
early and late stages of AMD. From 1984 to 2002, a total of 71,494 women from NHS and
41,564 men from HPFS were studied. At baseline, all participants were 50 years or older, and had
no diagnosis of AMD.
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Concerning advanced AMD, the overall result showed that L/Z intake had a possible
inverse association with advanced neovascular AMD in the NHS/HPFS populations. For the 442
participants who were observed to develop neovascular AMD after 18 years, increased L/Z intake
appeared to be weakly associated with reduced risk neovascular AMD (RR = 0.72). When
comparing the L/Z intake levels in the NHS/HPFS cohort versus those of the BMES cohort, the
L/Z intakes in NHS/HPFS were generally much higher. The lowest quintile intake was 1390
μg/day for NHS/HPFS, as compared to the much lower 288 μg/day lowest quintile intake for
BMES. The highest quintile intake was 5320 μg/day for NHS/HPFS, as compared to the much
lower 1466 μg/day highest quintile intake for BMES. Likely, the high L/Z intakes of NHS/HPFS
reflect the generally healthier lifestyle of the study’s participants, who were all health care
professionals. It is possible that the NHS/HPFS study may have had a ceiling effect, in which
most participants consumed significant amounts of L/Z so there was not much room to observe
the effects of very high or very low L/Z intake. Nonetheless, the collective results of NHS/HPFS
and BMES so far suggest that over a wide range of L/Z levels, L/Z may have a protective effect
against advanced neovascular AMD.
Concerning early AMD, the overall result of the NHS/HPFS study showed that L/Z
intake had no association with early AMD, similar to BMES’s result. Although 673 participants
were observed to develop early AMD, L/Z intake did not appear to be a protective or risk factor
into the 18-year incidence of early AMD. Specifically, NHS/HPFS’s observed lack of association
between L/Z intakes of more than 1350 μg/day and risk of early AMD is consistent with BMES’s
observed lack of association between L/Z intakes of 1466 μg/day and early AMD. Thus, the 18year NHS/HPFS further supported BMES’s finding that at high levels of L/Z, there is no
association with early AMD.
Generally, the 18-year NHS/HPFS study drew similar conclusions to the collated BMES
studies. Both prospective studies suggested that L/Z intake was overall not associated with early
AMD, but may be inversely associated with neovascular AMD. This conclusion further supports
a protective role for L/Z against AMD progression but not initiation. Figure 8B shows that L/Z
has a greater role in inhibiting progression to advanced AMD than in inhibiting onset of early
AMD.
When the participants of the NHS/HPFS study were followed-up after another 8 years in
a different report, similar results were observed. In a 26-year prospective study of the same
NHS/HPFS cohort, Wu sought to assess the association between dietary L/Z intake and AMD,
with a distinct focus on intermediate and advanced AMD.40 As continuation from the NHS/HPFS
study, 63,443 women from NHS and 38,603 men from HPFS were reexamined after another 8
years. Notably, the analysis of L/Z intake scores differed from the previous 18-year study. In this
study, dietary L/Z intakes were converted into predicted plasma levels of L/Z. The main
advantage to plasma L/Z levels are that they reflect the bioavailable levels of L/Z in foods.
Bioavailability refers to the proportion of ingested L/Z that is delivered to the bloodstream.41 The
absolute amount of L/Z in foods may not equal the amount of L/Z that is ultimately absorbed into
the bloodstream, due to limiting factors such as physical containment in the food matrix,
interaction with dietary fat, and malnutrition. Therefore, L/Z levels calculated directly from FFQs
may not adequately represent biologically relevant dosages.
Consistent with the results of the 18-year NHS/HPFS study, the extended 26-year followup indicated that L/Z intake had a possible inverse association with advanced neovascular AMD.
During the additional 8 years of follow-up, an extra 676 advanced AMD cases, for a total of 1118
cases, were reported. The addition of a large number of AMD cases provided a larger sample size
that gave more reliability to the observed inverse association between L/Z and advanced AMD.
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The highest quintile of plasma L/Z level was found to be associated with a 41% decreased risk of
advanced AMD (RR = 0.59). Thus, higher intake of bioavailable L/Z was associated with a longterm reduced risk of advanced neovascular AMD.
In contrast, L/Z intake was not associated with intermediate AMD. For the 1361
participants who were observed to display intermediate AMD after 26 years, the highest quintile
of plasma L/Z level did not appear to be related to occurrence of intermediate AMD (RR = 0.93).
This finding of a lack of association with intermediate AMD further supported the suggested
mechanism of L/Z’s protective effect. Based on the two NHS/HPFS studies and two BMES
studies, the lack of association with both early and intermediate AMD advocate a protective role
for dietary L/Z in AMD progression rather than initiation. As depicted in Figure 8B, these studies
suggest that L/Z may not prevent the onset of early AMD, but may delay the development of
early AMD to advanced AMD.
2.1.4 Evaluation of Epidemiological Results
A major limitation of cross-sectional and prospective studies is that they can only
establish correlations, and not causality. In other words, the observed inverse correlation between
increased dietary L/Z intake and reduced cases of advanced AMD does not imply that L/Z has a
direct protective effect. For example, there may be more people with AMD in the group
consuming the lowest quintile of L/Z simply because people with macular degeneration eat fewer
fruits and vegetables due to the difficulty of preparation. Similarly, people diagnosed with AMD
may have selectively recalled worse dietary habits than controls, highlighting a psychological
error inherent to the recall method of FFQs. Consequently, it would be reasonable to err on the
side of caution when accepting these studies’ results about the protective effects of L/Z.
However, support for L/Z’s direct involvement in reducing risk of AMD has been shown
in studies that investigated macular pigment optical density (MPOD), in addition to L/Z intake
and AMD incidence. MPOD reflects the concentration of L/Z in the macula.42 Given that higher
levels of L/Z in the macula protects cells against oxidative damage, higher MPOD values are
expected to be associated with reduced AMD risk if L/Z directly modulates AMD development.
Indeed, these MPOD studies showed that the quantity of consumed L/Z determines MPOD, and
that high MPOD was associated with reduced risk of AMD.43-45 Thus, MPOD results provide
evidence that the observed correlations between dietary L/Z and AMD does in fact directly
involve L/Z.
2.1.5 Conclusion
Overall, the cross-sectional and prospective studies reported here suggest that dietary L/Z
may reduce the development of advanced neovascular AMD. Table 2 shows a compilation of the
main results from these epidemiological studies. Although various studies found contradictory
associations between L/Z and AMD, normalizing for the factors of age, level of L/Z intake, and
type of AMD produced more consistent results. Based on two case-control studies, the 1994
Seddon and 2002 Snellen studies, high dietary L/Z was found to be associated with reduced risk
of the neovascular form of advanced AMD. The purported beneficial effect of dietary L/Z was
further refined by age, in Mares-Perlman’s 2001 cross-sectional cohort study. Only in the
subgroup of participants aged 60-79 years was high dietary L/Z intake correlated with lower risk
of advanced AMD. Given that advanced AMD develops rapidly after age 80, dietary L/Z may
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only be protective in relatively younger persons who have not yet progressed past the initial
stages of advanced AMD.
More recently, prospective studies have further supported the protective role of dietary
L/Z. Starting in 1984, the NHS/HPFS populations were followed for 18-years and 26-years by
two separate studies. Concurrently, starting in 1992, the BMES population was followed for 5years and 10-years by two separate studies. Concerning early AMD, both BMES studies
suggested a weak association between dietary L/Z and early AMD, but only within a certain L/Z
intake range between 733 μg/day and 1466 μg/day. Concerning intermediate AMD, the 26-year
NHS/HPFS study found no association. Concerning advanced AMD, both the 10-year BMES
study and 26-year NHS/HPFS study observed strong inverse associations between dietary L/Z
and neovascular AMD. Altogether, dietary L/Z intake was more strongly associated with
advanced neovascular AMD than with either early AMD or intermediate AMD. Therefore,
dietary L/Z is likely only protective against the progression of AMD to its advanced stage, and
not protective against the initial occurrence of early AMD.

Genotype

Gene
Expression

Nutrients

Eye
Disease

Advanced AMD

Dietary L/Z

Figure 9. Personalized nutrition: Linking nutrition to eye disease. Dietary L/Z is a feasible
strategy to delay the progression of advanced AMD.

In the context of personalized nutrition, the results of these epidemiological studies justify the
feasibility of dietary L/Z as a strategy to delay the progression of AMD. Figure 9 depicts the
pathway by which personalized nutrition is applied to eye disease, highlighting a link between
nutrient intake and advanced AMD. Observed associations between high L/Z intake and reduced
risk for advanced AMD suggest that nutritional recommendations are, in fact, applicable to the
field of eye care. Notably, different studies investigating different populations found that L/Z may
be beneficial at different levels of intake. Thus, how can eye care providers make dietary
recommendations that will lead to the best outcome (such as no incidence of advanced AMD) for
each individual patient? One approach is to incorporate genomic information, in a strategy known
as personalized nutrition. Moving forward, the function of genes as a link between L/Z intake and
AMD risk will be discussed.
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Table 2. Epidemiological studies investigating the association between dietary L/Z intake and AMD.32-34,36,37,39,40

Cross-Sectional Studies
Reference

Study Design

Health Status

Seddon32

Cross-sectional
case-control
Cross-sectional

Advanced AMD

Population
Cohort
EDCCS

Advanced AMD

NHANES III

Cross-sectional
case-control

Advanced AMD

NA

72 cases
66 controls

60+

Prospective Studies
Reference
Study Design

Health Status

Participants

Flood36

Early AMD

Population
Cohort
BMES

Total 3,654

Age
Range
49 – 80+

BMES

Total 3,654

49 – 80+

NHS & HPFS

Total 113,058

50+

NHS & HPFS

Total 102,046

50+

Mares-Perlman33

Snellen34

Tan37
Cho39
Wu40

Prospective
(5 yrs)
Prospective
(10 yrs)
Prospective
(18 yrs)
Prospective
(26 yrs)

Early +
Advanced AMD
Early +
Advanced AMD
Intermediate +
Advanced AMD

Participants
356 cases
520 controls
Total 8,222

NA = not available.
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Age
Range
55 – 80
40 – 80+

Range of
L/Z Intake
336 μg –
3,455 μg
315 μg –
9,715 μg
NA

Results

Range of
L/Z Intake
288 μg –
1,466 μg
NA

Results

1,349 μg –
5,712 μg
1,848 μg –
5,468 μg

Increased LZ intake associated
with reduced risk for AMD
Dietary LZ was unrelated to
AMD
Lower LZ intake associated with
higher occurrence of neovascular
AMD

Dietary LZ was unrelated to
incidence of early AMD
Increased LZ intake may reduce
risk of advanced AMD
Dietary LZ was unrelated to
AMD
Increased LZ intake may reduce
risk of advanced AMD only

Chapter 3. Clinical Studies Demonstrating a Genetic Basis for AMD
Investigating the nutrigenomics of AMD warrants the question: is there even a genetic
basis for AMD? If AMD is not hereditary, it would seem frivolous to review the relationship
between dietary L/Z and genes related to AMD pathogenesis. Furthermore, application of
personalized nutrition to eye disease demands that genes are in some way involved in modulating
AMD risk.
Table 3 summarizes the results of clinical studies supporting a substantial genetic
contribution to AMD that will be discussed in detail in this chapter. A review of the literature that
specifically investigates the heritability of AMD is surprisingly limited and non-recent. Despite
the relative scarcity of heritability studies, all results point to at least some heritability for AMD.
As such, this section will present early first-degree relative studies and twin studies which argue
in favor of a genetic basis for AMD. Two exemplar first-degree relative studies and two exemplar
twin studies are chosen for inclusion here because they are the most current studies that use
similar methods of analyses.
3.1 First-Degree Relative Studies
Two first-degree relative studies support a genetic component in the incidence of
advanced AMD, as shown in Table 3. In 1997, Seddon aimed to determine whether advanced
AMD aggregates in families.46 To evaluate the familial contribution of AMD, this study
compared the prevalence of any AMD in relatives of case subjects with advanced AMD to the
prevalence of any AMD in relatives of control subjects without AMD. A total of 177 first-degree
relatives of 119 cases, were compared to 146 first-degree relatives of 72 controls. ORs were
calculated to determine whether relatives of cases had increased risk of AMD compared to
relatives of controls.
The results of this first-degree relative study revealed that advanced AMD does have a
familial component. Figure 10 shows that a higher percentage (23.7%) of case relatives reported
having AMD, compared to only 11.6% of control relatives reported having AMD. Thus, the
prevalence of AMD was significantly higher in relatives of cases than controls (OR = 2.4). When
looking specifically at the neovascular form of AMD, the prevalence was even higher. 26.9% of
the relatives of case subjects with neovascular AMD reported AMD (OR = 3.1), indicating that
relatives of neovascular cases had a 3-fold increased risk of developing AMD. Overall, the
prevalence of AMD was highest among first-degree relatives of cases with advanced neovascular
AMD. This suggests that advanced AMD does have a familial component, whether the
contribution be from genetic or shared environmental factors, or both. As such, the extent of
genetic contribution remained to be investigated.
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Cases (with AMD)

Controls (without AMD)

Case Relatives

Control Relatives

Figure 10. First-degree relative studies point to a genetic component for AMD. An orange figure
represents an individual with AMD, and a gray figure represents an individual without AMD.
There is greater prevalence of AMD among relatives of persons with AMD (23.7%) than among
relatives of persons without AMD (11.6%).

Consequently, one year later, Klaver sought to investigate to what extent advanced AMD
is genetically determined.47 In 1998, Klaver used a familial aggregation study using the same
methodology as Seddon. In this study, 186 first-degree relatives of 87 cases with advanced AMD,
were compared with 343 first-degree relatives of 135 controls without AMD. The sample sizes
used here were comparable to those in Seddon’s study. However, analysis of AMD risk in this
study was more comprehensive. In addition to ORs, Klaver calculated RRs, lifetime risks, and
population-attributable risks to achieve a more complete analysis of the genetic contribution to
AMD.
The results of this first-degree study supported the findings of Seddon. The prevalence of
AMD was significantly higher in relatives of cases with advanced AMD (OR = 19.8). The
lifetime risk of advanced AMD was estimated to be 50% for case relatives, which was
significantly higher than the 12% risk for control relatives (RR = 4.2). The population-attributable
risk, which estimated the proportion of advanced AMD attributable to a genetic factor in the total
population, was determined to be 23%. Thus, this study concluded that approximately one quarter
of all advanced AMD was genetically determined. Overall, the two familial aggregation studies
suggested that genetics indeed plays an important role in the pathogenesis of advanced AMD.
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3.2 Twin Studies
The twin studies presented here offer insight into the relative contributions of both
genetic and environmental factors to AMD. Two twin studies support genetics as having a larger
contribution to incidence of AMD than environmental factors, as shown in Table 3.
In 2003, a twin study performed by Grizzard aimed to use concordance rates to evaluate
the genetic contribution in AMD.48 A total of 25 twin pairs aged 63 to 85 years were included.
This age range places the twin participants at high risk of developing AMD. Fifteen pairs were
monozygotic (MZ) and 10 pairs were dizygotic (DZ). To analyze genetic contribution, each twin
pair was assigned to one of the three classifications shown in Figure 11. Twin pairs were
classified as either concordant (both twins have AMD, in a similar stage), intermediate (both
twins have AMD, but in different stages), or discordant (one twin has AMD and the other twin
does not have AMD).
Concordant

Advanced AMD

Advanced AMD

Intermediate

Advanced AMD

Early AMD

Discordant

Advanced AMD

No AMD

Figure 11. Classification schemes for concordant, intermediate, and discordant twins. Twins
classified as concordant both have similar types of AMD. Twins classified as intermediate have
different types of AMD. A twin pair classified as discordant contains one twin with AMD and one
twin without AMD.

The overall results suggested that there is a genetic component to AMD. On average,
around 11 of the 15 (73%) MZ pairs were classified as concordant, and none (0%) were classified
as discordant. Of the 10 DZ pairs, only one was classified as concordant (10%), and an average of
five (50%) were classified as discordant. Given that the majority (73%) of MZ pairs were
concordant, and only one (10%) DZ pair was concordant, there appeared to be a significant
positive association between monozygosity and concordance for AMD.
Ultimately, this study suggested that genetics appears to play an important role in the
etiology of AMD. However, this study did not differentiate between early and advanced AMD,
nor did it quantify the genetic influence on AMD.
Two years later, Seddon aimed to calculate the impact of genetic and environmental
factors on AMD.49 In 2005, Seddon published a twin study that quantified the genetic influence
on AMD and specified the heritability of the advanced stage of AMD, in particular.49 In this study
a total of 391 twin pairs aged 78 to 88 years, along with 58 singletons, were included. This age
range places the participants at high risk of developing advanced forms of AMD. 210 pairs were
MZ and 181 pairs were DZ.
The overall results suggested that AMD has a large genetic component, especially the
advanced forms. When looking at concordance rates, 55% of MZ pairs were concordant for
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intermediate and advanced AMD, as compared to only 25% concordance in DZ pairs. These
concordance rates differ from Grizzard’s 73% MZ concordance and 10% DZ concordance, which
is expected given the large differences in sample size and cohort demographics. Nonetheless,
both studies show that MZ twins display higher concordance of AMD than DZ twins. The
relatively higher concordance in MZ twins supports a genetic contribution to AMD. Figure 12
depicts the observed concordance rates for advanced AMD, specifically. When focusing on the
advanced forms of AMD, concordance rates were 18% in MZ twins and 6% in DZ twins. Once
again, the relatively higher concordance in MZ twins suggests a genetic component for advanced
AMD.
Monozygotic Twins

Dizygotic Twins
Twin pair concordant
for advanced AMD
Twin pair

Figure 12. Concordance rates in twins point to a genetic component for advanced AMD. There is
higher concordance of advanced AMD in MZ twins (18%) than DZ twins (6%).

In addition to confirming that genes are involved in incidence of AMD, this study was
notable for also quantifying the relative contributions of genes and the environment on AMD.
Heritability was estimated to be 0.46 for any AMD and 0.71 for advanced AMD, suggesting
higher heritability of advanced forms. Environmental factors unique to each twin were estimated
to explain between 19% and 37% of the variation in AMD stage. Overall, genetic factors were
determined to play a substantial role in advanced AMD, while unique environments play a
moderate role in development of AMD. Looking forward, these results highlight the need to find
and investigate AMD-related genes.
The methodologies used by Grizzard and Seddon differed in terms of sample size,
participants, and AMD classification. In contrast to Grizzard’s study, the sample size of Seddon’s
study was much larger, allowing for more stable analysis of subgroups. However, despite the
large sample size, Seddon’s study was limited by its specific participant demographic.
Participants only included male twin pairs born between 1917 and 1927 who served in the US
armed forces, meaning that the results of this specific cohort may not be applicable to the general
population. Furthermore, whereas Grizzard only included twin pairs in which at least one twin
had AMD, Seddon did include twins without AMD. In fact, 39% of the total sample did not have
AMD, allowing Seddon to calculate heritability estimates for AMD. In contrast to Grizzard’s
study, in which any sign of AMD was generalized as a positive AMD diagnosis, Seddon’s study
differentiated between the different stages of AMD. Based on a 5-stage grading system, AMD
was classified as none (grade 1), early (grade 2), intermediate (grade 3), advanced dry (grade 4),
or advanced neovascular (grade 5). Also distinct to this study was the inclusion of singletons in
the analyses. The advantage to including singletons was that they could provide additional
information about the association of traits within individuals. Despite differences in
methodologies, both twin studies arrived at similar conclusions pointing to AMD as a heritable
disease.
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3.3 Conclusion
Overall, the first-degree relative studies and twin studies reported here confirm that there
is a large genetic contribution to AMD. The two first-degree relative studies showed that an
individual who was related to someone with advanced AMD was more likely to also have AMD,
than an individual who was not related to someone with advanced AMD. The two twin studies
showed that MZ twins were more likely to have similar stages of AMD than DZ twins. Thus,
genetics likely has a larger role in the etiology of AMD than environmental factors.

Genotype

Gene
Expression

Nutrients

Eye
Disease

Advanced AMD

Dietary L/Z

Figure 13. Personalized nutrition: Establishing a genetic basis for the eye disease AMD.

In the context of personalized nutrition, these heritability studies lay down a foundation
establishing a strong genetic basis for AMD. Genes were shown to modulate occurrence of AMD,
justifying further investigation into how genes may act as a link between dietary L/Z intake and
AMD risk. Figure 13 highlights two points in the L/Z-AMD pathway at which genetic
information can be used to create unique dietary recommendations that lead to the greatest
reduced risk of AMD in individual patients. Moving forward, genotype and gene expression will
be explored in relation to L/Z levels and AMD pathogenesis.
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Table 3. Clinical studies supporting a substantial genetic contribution to AMD. 46-49

First-Degree Relative Studies
Reference Health Status
Participants
46
Seddon
Advanced AMD 119 cases
in cases
177 first-degree case relatives
72 controls
146 first-degree control relatives
Klaver47

Advanced AMD
in cases

Twin Studies
Reference Health Status
Grizzard48 Any AMD

Seddon49

Advanced AMD

Analysis
Compared prevalence of AMD in
case relatives vs prevalence of
AMD in control relatives

Results
Prevalence of AMD was significantly
higher in relatives of cases than
controls. Advanced AMD does have a
familial component.

87 cases
186 first-degree case relatives
135 controls
343 first-degree control relatives

Compared prevalence of AMD in
case relatives vs prevalence of
AMD in control relatives

Prevalence of AMD was significantly
higher in relatives of cases than
controls. 23% of all advanced AMD
was genetically determined.

Participants
25 twin pairs: 15 MZ + 10 DZ pairs

Analysis
Compared concordance rates
between MZ and DZ twin pairs

391 twin pairs: 210 MZ + 181 DZ pairs.
Plus 58 singletons.

Compared concordance rates
between MZ and DZ twin pairs.
Quantified relative contributions
of genes and the environment on
AMD.

Results
Concordance of AMD was
significantly higher in MZ twins than
DZ twins. Genetics is important in the
etiology of AMD.
Concordance of advanced AMD was
significantly higher in MZ twins than
DZ twins. Genetic factors play a larger
role in the etiology of AMD than
environmental factors.
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Chapter 4. Studies Evaluating How Genotype Affects Risk of Advanced AMD
Genotype refers to the genetic makeup, or set of genes, in a person’s cells.23 These genes
are largely responsible for an individual’s traits. Variations in genes between different persons
correlate to differential responses to diet and subsequent differential development of disease
states. This chapter will focus on how an individual’s genotype coordinates a unique response to
diet. Currently, the literature as a whole has discovered many genes that are implicated in AMD.
This review will only discuss genes related to L/Z transport to the retina.
Given a specific set of genes related to L/Z metabolism, certain individuals may be
predisposed to be at high risk of developing AMD. One factor that can increase an individual’s
AMD risk is the impairment of L/Z transport in the body. After consuming fruits and vegetables
in the diet, L/Z should be absorbed and transported to retinal cells, where they can accumulate in
the macula and protect against AMD. HDL (high-density lipoprotein) may be involved in AMD
pathogenesis due to its role as the major lipoprotein transporter of L and Z.24 Different variants in
HDL-associated genes may change the efficiency by which L/Z undergo uptake and transport into
the retina, thus modulating the risk of developing AMD.
4.1 Overview of High-Density Lipoprotein (HDL)
HDL is composed of both protein and lipid.50 The protein fraction of HDL consists of
apolipoproteins, while the lipid fraction includes phospholipids and cholesteryl esters. Out of all
the lipoproteins in the body, HDL contains the highest proportion of protein. Structurally, HDLs
are small spherical particles which have a polar outer shell and lipophilic inner core.
A function of HDL is to transport lipophilic L/Z.24 After L/Z-containing foods have been
digested, the fat-soluble L/Z must be coupled to a carrier in order to be transported in the aqueous
blood. HDL is such a carrier, providing the lipophilic environment necessary for L/Z to be
transported throughout the body. Once HDL-L/Z complexes reach the eye, HDL binds to
apoliproprotein E (apoE) receptors in the retina. Binding of HDL to their target retinal receptors
then releases L/Z into the retina.51 Therefore, variations in genes controlling HDL status may
modulate the amount of L/Z that is transported into the retina.
4.2 Variants in Genes Related to HDL Status
4.2.1 Methodology
Genetic variants that are important to a disease can be identified using a genome-wide
association study (GWAS). Use of GWAS has increased significantly in the past decade as a
result of large technological advancements in genotyping methods.52 In GWAS, a phenotype-togenotype approach is used to identify genetic variants that are significantly associated with
human diseases. First, a very large population is phenotypically separated into cases and controls,
based on whether they manifest the disease-of-interest. Then, all participants are genotyped to
detect genetic variants, also known as SNPs (single nucleotide polymorphisms). Next, the
frequency of genetic variants are compared between cases and controls. If there is greater
frequency of a certain genetic variant in the case population (with disease) than the control
population (without disease), then that variant is considered to be associated with the disease.
The main advantage to GWAS studies are that they are an unbiased, whole genome
approach to identifying novel genes linked to common and complex diseases.52 The results of
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GWAS are reliable, because there is a stringent threshold of statistical significance (typically P <
5 × 10−8) for a genetic variant to be considered associated with the disease. However, there are
some limitations to GWAS as well. Generally, GWAS may not accurately estimate the effect
sizes and heritability explained by causal gene variants.53 The association signals detected from
GWAS represent linkage between a common “tag” SNP and a causal SNP with a small effect
size; thus, GWAS results may only explain a minor proportion of disease heritability.
Additionally, common gene variants with subtle effects could be difficult to recognize as causal
for the disease.
This section will present four SNPs in three separate genes that were discovered by
GWAS to be associated with AMD. Among all the AMD-associated genes implicated in GWAS
studies, three genes were chosen for inclusion because they have important functions in the
metabolism of HDL. Table 4 shows that a review of the LIPC, CETP, and ABCA1 genes will
relate HDL status to AMD risk, pointing to HDL-mediated L/Z transport as one mechanism by
which individuals are at differential risk of developing AMD.
Table 4. Reported associations between variants in genes related to HDL status and risk of AMD.54-57

Gene
LIPC
CETP

ABCA1

Function
LIPC is involved in cellular
uptake of HDL
CETP is involved in the
synthesis and degradation of
HDL
ABCA1 is involved in
mediating the formation of
HDL particles

Locus
rs10468017
rs493258
rs3764261

Genotype
Low AMD risk High AMD risk
TT
CC
TT
CC
CC
AA

rs1883025

TT

CC

4.2.2 Hepatic Lipase gene (LIPC)
The hepatic lipase gene (LIPC) encodes hepatic triglyceride lipase (LIPC), which is an
important enzyme in HDL metabolism that mediates HDL uptake at the cell surface.54
Specifically, LIPC may function as a bridging factor for receptor-mediated HDL uptake. As
depicted in Figure 14, LIPC that is expressed in the retina may promote the association of HDL
with HDL-receptors on cell membranes, thus increasing the amount of L/Z that is delivered to
retinal cells. Accordingly, genetic variants of LIPC may be implicated in AMD pathogenesis due
to variation in the retinal uptake of L/Z by HDL.54 Here, GWAS studies have identified two
genetic variants in the LIPC gene that are associated with advanced AMD, as shown in Table 4.
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Figure 14. The role of LIPC in HDL-mediated L/Z uptake into retinal cells. In the macula of the
eye, LIPC may function as a bridging factor for receptor-mediated HDL uptake.

4.2.2.1 Locus rs493258
The rs493258 locus, or position, near LIPC was found to be significantly associated with
AMD in two GWAS studies.54,55 In 2010, Chen reported that a GWAS study had identified new
genetic variants in LIPC that were associated with any AMD.55 A total of 7,749 cases and 4,625
controls were genotyped. The results of this study found that the rs493258 locus in a promoter
region near LIPC on chromosome 15 was strongly associated with AMD. Specifically, the C
allele at rs493258 was observed to be associated with increased risk of AMD (OR = 1.14,
overall P = 1.3 × 10−7). In this study, even though the association signal for a variant at LIPC
rs493258 was strong, the association was not statistically significant. However, LIPC rs493258’s
association with AMD was found to be significant in a companion GWAS study.54
In the companion 2010 GWAS study, Neale similarly identified new genetic variants in
LIPC that were associated with AMD.54 However, Neale’s study differed from the previous study
by only including cases with advanced AMD. Thus, a slightly smaller sample size of 5,789 cases
and 4,234 controls were genotyped. The results of this study found the rs493258 locus near LIPC
to be significantly associated with advanced AMD (P = 1.61 × 10−8).
A 2013 GWAS study by Lee aimed to replicate Neale’s GWAS finding of a significant
association between LIPC and advanced AMD.56 As a smaller GWAS study with 3,785 cases of
advanced AMD and 2,009 controls, Lee specifically focused on confirming the associations
between previously-reported LIPC variants and advanced AMD. The results were indeed
consistent with Neale’s large GWAS, in which the LIPC variant rs493258 was significantly
associated with advanced AMD (P = 1.21× 10−4).
The association of LIPC risk loci and advanced AMD was further confirmed by Cipriani
in a 2012 GWAS study of participants living in the UK.57 Using a small discovery cohort of 893
cases and 2199 controls, Cipriani’s study aimed to confirm LIPC rs493258 as a probable AMD
susceptibility locus. Indeed, their results showed that the LIPC variant rs493258 was weakly
associated with advanced AMD (P = 0.04). Specifically, the T allele at rs493258 had a weak
protective effect against advanced AMD (OR = 0.89). Taken together with Chen’s results, the C
allele at rs493258 was associated with increased risk of AMD, and the T allele was associated
with decreased risk of advanced AMD.
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4.2.2.2 Locus rs10468017
Another genetic variant in the promoter region of LIPC, the rs10468017 locus, was found
to be significantly associated with advanced AMD in two GWAS studies.54,56 In Neale’s 2010
GWAS study, the LIPC variant that was most strongly associated with advanced AMD was the
functional promoter variant, rs10468017 (P = 1.34× 10−8).54 In Lee’s smaller-sized GWAS study,
rs10468017 was confirmed to be significantly associated with advanced AMD (P = 1.67× 10−3).56
Specifically, the minor allele, T, was associated with a reduced risk of AMD (OR =
0.82).54 When the neovascular form of advanced AMD was analyzed separately, the T allele had
a similar protective effect (OR = 0.77).
In contrast, LIPC rs10468017 was not found to be associated with advanced AMD in
Cipriani’s small GWAS study of UK participants.57 Using a small discovery cohort of 893 cases
and 2199 controls, the T allele of LIPC rs10468017 was not associated with reduced risk of
advanced AMD (P = 0.11, OR = 0.91). However, this study was limited by its small sample size.
The discovery GWAS did not have the statistical power necessary to detect weak associations,
such as that between LIPC rs10468017 and advanced AMD.
4.2.2.3 LIPC, HDL Levels, and AMD Pathogenesis
Overall, LIPC variants at rs493258 and rs10468017 may confer differential risk of
developing advanced AMD. As shown in Table 4, individuals with TT alleles at rs493258 or
rs10468017 were less likely to have advanced AMD. On the other hand, individuals with CC
alleles at rs493258 or rs10468017 were more likely to have advanced AMD.
Regarding the contribution of LIPC to AMD pathogenesis, HDL-associated genetic
variants may modulate the amount of L/Z that is delivered into the retina. In essence, how do
serum levels of HDL affect the risk of developing AMD, if at all? Given that the T allele is
known to increase HDL levels,58 the relationship between LIPC-modulated HDL levels and
advanced AMD could be characterized. Namely, an HDL-raising allele of LIPC was suggested to
decrease risk of advanced AMD. The implications of this effect will be discussed in the
conclusions section.
4.2.3 Cholesteryl Ester Transfer Protein gene (CETP)
The cholesteryl ester transfer protein gene (CETP) encodes cholesteryl ester transfer
protein (CETP), which is involved in the transfer of cholesteryl ester and triglycerides between
HDL and another lipoprotein, VLDL (Very Low-Density Lipoprotein).54 Thus, CETP plays an
important role in the synthesis and degradation of HDL.
Figure 15 shows how CETP impacts HDL and L/Z status. CETP transfers cholesteryl
esters from HDL to VLDL (a), and transfers triglycerides from VLDL to HDL (b). Thus, CETP
can decrease or increase levels of plasma HDL, respectively. If there are decreased levels of
HDL, less L/Z is able to be transported by HDL to the retina (c). With less HDL available to bind
to HDL-receptors (d), there is decreased delivery of L/Z into retinal cells (e). On the other hand,
if there are increased levels of HDL, more L/Z is able to be transported by HDL to the retina (f).
With more HDL available to bind to cell membrane HDL-receptors (g), there is increased
delivery of L/Z into retinal cells (h).
Given its role in HDL synthesis and degradation, CETP may modulate the amount of
HDL that are available to deliver L/Z into retinal cells. Accordingly, genetic variants of CETP
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may be implicated in AMD pathogenesis due to variation in the uptake and transport of L/Z by
HDL.54 Here, GWAS studies have identified one genetic variant in the CETP gene that is
associated with AMD, as shown in Table 4.

Blood Vessel

a

VLDL

HDL

CETP

L+Z

b
f

c

HDL
L+Z

d
e
L+Z

g
HDL-Receptor

h

Retinal Cell

Figure 15. The role of CETP in HDL metabolism and L/Z transport in retinal cells. CETP is
involved in the synthesis and degradation of plasma HDL. Thus, CETP may modulate the amount
of HDL-carrying L/Z that reach the retina.

4.2.3.1 Locus rs3764261
The rs3764261 promoter locus near CETP was found to be significantly associated with
AMD in two GWAS studies.54,55 In 2010, Chen’s large GWAS study that genotyped 7,749 cases
and 4,625 controls identified new associations between CETP variants and any AMD.55 The
results of Chen’s study found that the A allele at rs3764261 on chromosome 16 was found to be
associated with increased risk of AMD (OR = 1.19, overall P = 7.4 × 10−7). It should be noted
that even though the association signal near CETP was strong, it did not reach genome-wide
significance in Chen’s study. Nonetheless, the CETP signal likely reflected a real association with
AMD, since less than 0.3 loci per scan were expected to reach P < 3 × 10−7 by chance.
Similar results were reported in a companion 2010 GWAS study.54 In Neale’s slightly
smaller GWAS of 5,789 cases and 4,234 controls, the CETP variant at rs3764261 was found to be
related to the advanced stage of AMD. Consistent with Chen’s result, the A allele was found to be
weakly associated with increased risk of AMD (P = 1.41× 10−7).
In contrast, CETP rs3764261 was not found to be associated with advanced AMD in
Cipriani’s small GWAS study of UK participants.57 Using a small discovery cohort of 893 cases
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and 2199 controls, this small GWAS did not appear to support the previously reported CETP
rs3764261 as a probable AMD susceptibility locus. However, Cipriani’s study was limited by its
small sample size. The discovery GWAS did not have the statistical power necessary to detect
weak associations, such as that between CETP rs3764261 and advanced AMD.
4.2.3.2 CETP, HDL Levels, and AMD Pathogenesis
Overall, CETP variants at rs3764261 may confer differential risk of developing AMD. As
shown in Table 4, individuals with AA alleles at rs3764261 were more likely to have AMD. On
the other hand, individuals with CC alleles at rs3764261 were less likely to have AMD.
Regarding the relationship between CETP and AMD pathogenesis, how do serum levels
of HDL affect the risk of developing AMD, if at all? Given that the A allele is known to increase
HDL levels,59 the relationship between CETP-modulated HDL levels and advanced AMD could
be characterized. Namely, an HDL-raising allele of CETP was suggested to increase risk of
advanced AMD. Interestingly, this increased risk is opposite of the protective effect observed
with the HDL-raising LIPC allele. Although both CETP and LIPC alleles raise HDL levels in the
blood, they may have opposing effects on AMD risk. The implications of these effects will be
discussed in the conclusions section.
4.2.4 ATP-Binding Cassette Protein gene (ABCA1)
The ATP binding cassette subfamily A member 1 gene (ABCA1) encodes for an ATPbinding cassette protein (ABCA1), which moves cholesterol across cell membranes to the outside
of the cell.60 Thus, ABCA1 functions as a cholesterol efflux pump.
Figure 16 shows how ABCA1 impacts HDL and L/Z status. In the body and eyes,
ABCA1 is involved in efflux of cholesterol from somatic cells (a) and retinal cells (b). Once
outside the cell, free cholesterol is transported in the bloodstream to the liver (c). In the liver,
cholesterol then combines with other fats and proteins to form HDL (d). These HDL can then
pick up L/Z in the bloodstream (e), and carry these dietary carotenoids to the retina (f). In the
retina, HDL can bind to HDL-receptors (g) and deliver L/Z into retinal cells (h).
Given its role in cholesterol efflux, ABCA1 may modulate the amount of HDL that are
synthesized and available to deliver L/Z into retinal cells. Accordingly, genetic variants of
ABCA1 may be implicated in AMD pathogenesis due to variation in the uptake and transport of
L/Z by HDL.54 Here, GWAS studies have identified one genetic variant in the ABCA1 gene that is
associated with AMD, as shown in Table 4.
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Figure 16. The role of ABCA1 in HDL metabolism and L/Z transport in retinal cells. ABCA1
may modulate the amount of HDL that is synthesized, thus regulating how much HDL is available
to deliver L/Z into retinal cells.

4.2.4.1 Locus rs1883025
The rs1883025 locus in an intronic region of ABCA1 was found to be significantly
associated with AMD in two GWAS studies.54,55 In 2010, Chen’s large GWAS study that
genotyped 7,749 cases and 4,625 controls identified new associations between ABCA1 variants
and any AMD.55 Generally, HDL-associated alleles near ABCA1 showed weak associations with
AMD (P = 5.6 × 10−4). Specifically, the C allele at rs1883025 was associated with increased risk
of AMD (OR = 1.15).
Similar results were reported in a companion 2010 GWAS study. In Neale’s slightly
smaller GWAS of 5,789 cases and 4,234 controls, the potential association between rs1883925
and the advanced stage of AMD was confirmed.54 Consistent with Chen’s result, the ABCA1
variant at rs1883025 was weakly associated with advanced AMD (P = 9.73 × 10−4).
4.2.4.2 ABCA1, HDL Levels, and AMD Pathogenesis
Overall, ABCA1 variants at rs1883025 may confer differential risk of developing AMD.
As shown in Table 4, individuals with CC alleles at rs3764261 were more likely to have AMD.
On the other hand, individuals with TT alleles at rs3764261 were less likely to have AMD.
Regarding the relationship between ABCA1 and AMD pathogenesis, how do serum levels
of HDL affect the risk of developing AMD, if at all? Since the C allele is known to increase HDL
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levels,61 the relationship between ABCA1-modulated HDL levels and advanced AMD could be
characterized. Namely, an HDL-raising allele of ABCA1 was suggested to increase risk of
advanced AMD. Interestingly, this increased risk is opposite of the protective effect observed
with the HDL-raising LIPC allele, but consistent with the risk-increasing effect of the HDLraising LIPC allele. The implication of these observed inconsistencies will be discussed in the
conclusions section.
4.3 Evaluation of GWAS Results
It should be noted that these studies have limitations that may affect the interpretation of
overall results. Notably, only Caucasian participants were included in these GWAS studies. It is
possible that populations of different ethnicities may affect the observed associations between
genetic variants and AMD. Furthermore, the range of sampled geographical locations was
restricted, with three GWAS studies conducted in the US, and only one conducted in the UK.
Therefore, the reported findings may not be generalized. It is necessary to investigate associations
in different ethnic populations from various regions of the world. Consideration should also be
given to the fact that most of these GWAS studies implicated many other genes, in addition to
LIPC, CETP, and ABCA1, that are involved in various other processes in the body. Thus, the
effects of these three HDL-related genes on L/Z status, and consequently AMD development,
may not be very large.
4.4 Conclusion
Overall, GWAS studies have identified genetic variants, at rs493258 and rs10468017
(LIPC), rs3764261 (CETP), and rs1883025 (ABCA1), that are involved in HDL metabolism and
may be associated with advanced AMD. So far, these SNPs have not been strongly associated
with other diseases. It has been suggested that these genetic variants may contribute to coronary
artery disease, which is plausible given their roles in lipid metabolism.58,59,61 However, these
associations still need to be clarified.
On the other hand, more research has focused on the association between these HDLrelated SNPs and AMD. Because L and Z are preferentially carried on HDLs, blood HDL
distribution may be an important indicator of L/Z accumulation in the retina and, subsequently,
AMD risk.24 However, Table 5 shows that there does not appear to be a straightforward
correlation between HDL levels and AMD. The HDL-raising T allele of LIPC was suggested to
decrease risk for AMD. In contrast, the HDL-raising A allele of CETP and HDL-raising C allele
of ABCA1 may increase risk for AMD, although these associations are currently not genome-wide
significant. Altogether, three alleles that increase HDL levels were observed to impact AMD risk
in opposite directions. The observed contradictory associations between serum HDL and
advanced AMD suggest that HDL levels do not have a causal effect on advanced AMD.54 Instead,
there must be alternative biologic mechanisms by which HDL-associated gene variants affect
susceptibility of AMD.
Table 5. Reported relationships between risk of AMD and the HDL-raising alleles of three genes involved
in HDL metabolism.58,59,61

HDL-raising allele

LIPC
Decreased AMD risk

CETP
Increased AMD risk
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ABCA1
Increased AMD risk

One alternative biologic mechanism involves changes in HDL-related efficiency of L/Z
delivery. For example, variants in the rs493258 or rs10468017 promoter region of LIPC influence
the amount of LIPC that is transcribed and available to be translated into active enzymes. The
concentration of LIPC enzymes in the retina may consequently determine the efficiency by which
HDL particles bind to HDL-receptors. The more LIPC there is in the retina, the more likely it is
that HDL will associate with its receptor, delivering more L/Z into retinal cells. For CETP and
ABCA1, current understanding of their effects on HDL metabolism is limited to their effects on
serum HDL levels. Alternative mechanisms by which CETP and ABCA1 impact HDL-associated
L/Z delivery into the retina should be explored.
In the context of personalized nutrition, the discovery of AMD-susceptibility alleles
highlights the advantage to using genomic information to form nutritional recommendations that
effectively decrease risk of advanced AMD. Based on HDL’s suggested role as the major
lipoprotein transporter of L/Z,24 genetic variants associated with HDL status may affect how
much L/Z is transported into the retina. Figure 17 depicts how genotyping fits into the concept of
personalized nutrition. The genetic information extracted from genotyping for HDL-related
genetic variants is important for pinpointing individuals at high-risk for AMD. Such high-risk
individuals may require higher dietary intakes of L/Z.
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Figure 17. Personalized nutrition: Genotyping for genetic variants in HDL-related genes.
Individuals with certain alleles in HDL-related genes are at higher risk for AMD and require
higher intakes of L/Z.

This section reviewed four genetic variants that may be involved in HDL-related L/Z
transport. After L/Z has been transported by HDL to the retina and taken up by retinal cells, they
may then regulate the transcription of genes. The next section will investigate the effect of L on
inflammatory gene expression, pointing to a genetic mechanism by which L is protective against
the development of AMD.
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Chapter 5. Studies Evaluating How L Alters Expression of Genes Involved in AMD
Pathogenesis
Between the dietary macular pigments L and Z, L is found at greater concentration in a
wider variety of fruits and vegetables. Correspondingly, most published studies elucidating the
mechanism by which dietary macular pigments affect AMD have focused solely on the effects of
L. Currently, L is widely recognized as protecting eye tissue against photooxidative damage via
two mechanisms: first as a filter for harmful high-energy light and second as an antioxidant that
quenches ROS.12 Additionally, a chronic inflammatory response may be involved in AMD
pathogenesis.25 However, the role of L in ocular inflammation has been much less-studied. In this
section, three studies will be presented to understand the genetic mechanism by which L is antiinflammatory against development of AMD. Table 6 compares the methodologies of three
studies, all of which used the in vitro system of RAW264.7 macrophages to investigate the effect
of L on an inflammatory response potentially involved in AMD pathogenesis. All studies
stimulated inflammatory conditions in a model cell, and compared levels of target molecules
before and after L incubation.
Table 6. Studies using the in vitro system of RAW264.7 macrophages to investigate the effect of lutein on
an inflammatory response potentially involved in AMD pathogenesis. Comparison of inflammatory
molecule expression in conditions of inflammation with and without L reveal the mechanism by which L is
anti-inflammatory.

Study

System

Lutein

RAW264.7 cells

Inflammation
Stimulation
1000 ng/mL LPS

18 μM

Target Inflammatory
Molecules
iNOS, COX-2, IκB

Jin62
Izumi-Nagai63

RAW264.7 cells

100 ng/mL LPS

18 μM

VEGF

Kim64

RAW264.7 cells

100 ng/mL LPS
200 μM H2O2

20 μM

iNOS, COX-2, IκB, NO,
PGE2, NF-κB, H2O2, IKK,
Akt, NIK, PTEN, and PI3K

5.1 Inflammatory Response
5.1.1 Methods in vitro: RAW264.7 cells
All three studies used the in vitro system of RAW264.7 cells to study the antiinflammatory effects of L. As a mouse macrophage cell line, RAW264.7 was the chosen model
system because these cells are very sensitive to stimulation by the endotoxin LPS
(lipopolysaccharide), and they respond by activating proinflammatory targets.65 Thus,
inflammatory conditions that may be involved in AMD pathogenesis were simulated in
RAW264.7 cells by incubation with LPS. It should be noted that although RAW264.7 cells are
not the types of macrophages found in an eye with AMD, they are a useful model because they
can be easily manipulated to mimic the inflammatory conditions of AMD. Similarly, although
LPS is not known to directly cause AMD, LPS was used as a model for a type of inflammation
leading to AMD because RAW264.7 cells are easily stimulated by LPS.
Theoretically, LPS-stimulation should increase the expression of proinflammatory genes,
while the addition of L should suppress the LPS-stimulated increase in expression of
proinflammatory genes. Thus, the levels of genes and molecules in RAW264.7 cells were
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analyzed in three conditions: no stimulation, LPS-stimulation, and LPS-stimulation plus L.
Comparison between these three conditions revealed the inflammation-associated signaling
pathway that is targeted by L in the cell.
The methodology used to prepare RAW264.7 cells was similar in all three studies. First,
RAW264.7 cells were pretreated with various concentrations of L, ranging from 1 μg/mL to 100
μg/mL. Next, RAW264.7 cells were stimulated with LPS. One study used 1000 ng/mL LPS62,
while the other two studies used 100 ng/mL LPS.63,64 Lysates and/or total RNA were then
extracted from RAW264.7 cells and analyzed.
5.1.2 Methods in vitro: The Inflammatory Nuclear Factor NF-κB Pathway
The nuclear factor NF-kB pathway is widely accepted as a typical proinflammatory
signaling pathway.66 As a protein complex, NF-kB (nuclear factor kappa-light-chain-enhancer of
activated B cells) generally functions as a regulator of DNA transcription. NF-kB itself is a
central molecule in the inflammatory response, acting as a link between upstream
proinflammatory cytokines and downstream transcription of proinflammatory genes. Generally,
the NF-kB pathway is activated upon cellular stimulation, such as LPS-induced oxidative stress.
Stimulation initiates a signaling cascade of proinflammatory cytokines, leading to the activation
of NF-kB. Activated NF-κB dimers are released from a cytoplasmic NF-κB–IκB complex and
freed to translocate to the nucleus.67 Once inside the nucleus, NF-κB binds to enhancer and
promoter elements of proinflammatory genes. Ultimately, NF-κB induces the transcription of
proinflammatory cytokines, chemokines, and adhesion molecules.
The proinflammatory targets investigated by these three studies were all involved in the
NF-κB signaling pathway. Western blot analysis or ELISA (enzyme-linked immunosorbent
assay) was performed to measure relative protein levels. RT-PCR (reverse transcription
polymerase chain reaction) was performed to measure mRNA levels. EMSA (electrophoretic gel
mobility shift assay) was performed to measure binding activity between transcription factors and
DNA. ChIP (chromatin immunoprecipitation assay) was performed to determine what DNA
regions a transcription factor binds to.
Measurements were obtained for upstream mediators of the NF-κB pathway, proteins
directly participating in NF-κB activation, and genes transcribed by NF-κB activation. Table 7
describes the proteins and genes analyzed across the three studies. Upstream mediators of the NFκB pathway include H2O2 (hydrogen peroxide), PI3K (phosphoinositide 3-kinase), PTEN
(phosphatase and tensin homolog), IKK (inhibitor of nuclear factor kappa-B kinase), Akt (protein
kinase B), and NIK (nuclear factor-kappa-B-inducing kinase). Proteins directly participating in
NF-κB activation include NF-κB (nuclear factor kappa B) and IκB (inhibitor kappa B). Genes
transcribed by NF-κB activation include iNOS (inducible nitric oxide synthase), COX-2
(cyclooxygenase), and VEGF (vascular endothelial growth factor). Metabolites downstream of
NF-κB-activated genes were also measured, including NO (nitric oxide) and PGE2 (prostaglandin
E2).
Frequently, the protein levels of these genes were analyzed instead of mRNA levels.
Analyzing protein expression over RNA expression is advantageous because protein levels reflect
the subset of active RNA. Often, RNA can be silenced or degraded before being translated into
proteins. Thus, protein analysis reveals the proportion of RNA that actually leads to inflammatory
effects in the cell.
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Table 7. Proteins and genes involved in the inflammatory NF-κB pathway.

Section of NF-κB
Pathway
Genes transcribed by
NF-κB activation
Proteins directly
participating in NF-κB
activation

Upstream mediators of
the NF-κB pathway

Target

Form

Function

iNOS
COX-2
VEGF
IκB

Unphsophorylated

Proinflammatory gene/protein
Proinflammatory gene/protein
Proinflammatory protein
Binds to and sequesters NF-κB in
cytoplasm
Tagged for degradation; no longer
binds to NF-κB in cytoplasm
Inactive transcription factor
Active transcription factor that
binds to promoter region of DNA
Indirectly inactivates Akt
Does not inhibit Akt
Indirectly activates Akt
Phosphorylated (active) Akt
phosphorylates IKK
Phosphorylated (active) NIK
phosphorylates IKK
Phosphorylated (active) IKK
phosphorylates IκB

Phosphorylated
NF-κB

Cytosolic
Nuclear

PTEN
PI3K
Akt

Reduced
Oxidized
Phosphorylated

NIK

Phosphorylated

IKK

Phosphorylated

5.1.3 Results in vitro
The first study to investigate L’s effect on ocular inflammation in AMD pathogenesis
was reported in 2006.62 Using the in vitro system of RAW264.7 cells, Jin aimed to understand the
molecular mechanism by which L treatment affected LPS-induced RAW264.7 cells.62
The overall results showed that L had an anti-inflammatory effect in vitro. Before LPSstimulation, RAW264.7 cells had no expression of iNOS or COX-2 proteins. After LPSstimulation, expression of iNOS and COX-2 proteins increased dramatically (1.5 signal intensity
and 1.1 signal intensity, respectively). Notably, LPS-stimulated cells that were pretreated with L
had lower expression of both iNOS and COX-2 proteins. Thus, L inhibited LPS-induced
increases in the proinflammatory iNOS and COX-2 protein levels.
To elucidate the mechanism underlying L’s effect, the protein levels of IκB were
examined. Before LPS-stimulation, RAW264.7 cells had a large amount of IκB in the cytoplasm
(0.8 signal intensity). After LPS-stimulation, the amount of cytosolic IκB decreased significantly
(0.2 signal intensity). Notably, LPS-stimulated cells that were pretreated with L had increased
levels of cytosolic IκB. Thus, L likely inhibited the LPS-induced degradation of IκB in the
cytoplasm.
Jin’s results were supported by a separate study one year later. In 2007, Izumi-Nagai also
used the in vitro system of RAW264.7 cells to examine how L altered expression of a
proinflammatory molecule.63 In contrast to the previous study, this study investigated the change
in expression of an inflammatory protein, VEGF, specifically involved in development of
choroidal neovascularization (CNV). CNV occurs when new blood vessels form in the choroid
layer of the eye, which is the main criteria for diagnosing the neovascular form of advanced
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AMD. Thus, this study refined L’s anti-inflammatory mechanism to include regulation of VEGF,
which specifically promotes the development of advanced neovascular AMD.
The overall result showed that L had an anti-inflammatory effect in vitro. Before LPSstimulation, RAW264.7 cells had a low amount of VEGF protein (approximately 50 pg/mg).
After LPS-stimulation, there was a significantly increased amount of VEGF (approximately 110
pg/mg). Notably, LPS-stimulated cells that were pretreated with L had reduced levels of VEGF
(70-80 pg/mg). Thus, L inhibited the LPS-induced increase in VEGF.
From the previous two studies, L appeared to exert its anti-inflammatory effect by
inhibiting the production of proinflammatory proteins such as iNOS, COX-2, and VEGF. Figure
18 depicts one possible mechanism by which L is anti-inflammatory in RAW264.7 cells. In
untreated inflammatory conditions, cytosolic IκB is degraded. Degradation of IκB frees NF-κB,
which is normally bound to IκB in the cytoplasm, to translocate into the nucleus. NF-κB binds to
DNA and up-regulates the expression of proinflammatory genes encoding iNOS, COX-2, and
VEGF. However, Figure 18 depicts L-treated inflammatory conditions, in which L suppressed
degradation of cytosolic IκB. If cytosolic IκB is not degraded, NF-κB cannot be activated
(translocate from the cytoplasm into the nucleus). Consequently, there is decreased transcription
of inflammation-related genes, and ultimately a decreased amount of inflammatory proteins in the
cell.

LPS

Extracellular
Intracellular

IκB
Lutein

NF-κB
NF-κB
NF-κB

iNOS
COX-2
VEGF

Nucleus
Figure 18. The results of Jin62 and Izumi-Nagai63 showing lutein’s anti-inflammatory effect.
Incubating LPS-stimulated RAW264.7 cells with lutein inhibits the expression of proinflammatory
proteins, likely by suppressing the degradation of cytosolic IκB.

One year later, a comprehensive study further expanded this suggested mechanism for
L’s anti-inflammatory effect. In 2008, Kim used the in vitro system of RAW264.7 macrophages
to elucidate alternative mechanisms by which L may modulate immune responses.64 Improving
on the previous two studies, this study provided a comprehensive investigation into the
downstream targets of NF-κB pathway, NF-κB activation itself, and upstream modulators of NF-
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κB pathway. In doing so, other targets through which L could regulate transcription of
inflammation-related genes were discovered.
The overall results showed that L had an anti-inflammatory effect in vitro. L was
observed to inhibit cellular targets that will be generalized into three groups: 1) inflammationrelated genes and proteins, 2) NF-κB signaling, and 3) H2O2-stimulated signaling.
First, Figure 19 shows that L suppressed the expression of inﬂammation-related genes
and corresponding proteins. Consistent with the results of Jin’s 2006 study, L inhibited both the
iNOS-NO pathway and the COX2-PGE2 pathway. Before LPS-stimulation, RAW364.7 cells had
very low levels of iNOS mRNA, iNOS protein, NO (1 μM), COX-2 mRNA, COX-2 protein, and
PGE2 (1 ng/ml). After LPS-stimulation, RAW364.7 cells had increased levels of iNOS mRNA,
iNOS protein, NO (20 μM), COX-2 mRNA, COX-2 protein, and PGE2 (6 ng/ml). LPSstimulated cells that were pretreated with 20 μM L inhibited the changes seen with LPSstimulation: L decreased levels of iNOS mRNA, iNOS protein, NO (4 μM), COX-2 mRNA,
COX-2 protein, and PGE2 (3 μM). Thus, L was confirmed to decrease the production of proinflammatory molecules.

A

B

LPS

─

+

+

LPS

─

+

+

Lutein

─

─

+

Lutein

─

─

+

iNOS

iNOS

COX-2

COX-2

VEGF
IκB
p-IκB
cytosolic NF-κB
nuclear NF-κB
Figure 19. Adapted from Izumi-Nagai and Kim.63,64 Lutein inhibits LPS-induced NF-κB signaling
and downstream expression of inflammatory proteins. RAW264.7 cells were treated with LPS
(100 ng/ml) in the presence of lutein (20 μM). (A) Observed protein levels of inflammatory and
NF-κB molecules. (B) Observed mRNA levels of iNOS and COX-2.

Secondly, Figure 19A shows that L inhibited NF-κB signaling by decreasing both NF-κB
activation and NF-κB promoter activity. To refine the results of Jin’s 2006 study, which only
analyzed levels of cytosolic IκB, this study analyzed the levels and activity of NF-κB. These
measurements confirmed the NF-κB pathway as a target for L in down-regulating inflammatory
genes. Before LPS-stimulation, NF-κB were predominantly expressed in the cytosol, and there
was almost no binding between NF-κB and the iNOS promoter. After LPS-stimulation, NF-κB
were predominantly expressed in the nucleus, and there was significantly increased binding
between NF-κB and the iNOS promoter. LPS-stimulated cells that were pretreated with 20 μM L
inhibited the changes seen with LPS-stimulation: L increased cytosolic NF-κB and decreased
nuclear NF-κB, as well as decreased binding between NF-κB and the iNOS promoter. Thus, L
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decreased production of a proinflammatory protein by inhibiting the translocation of NF-κB into
the nucleus, such that less NF-κB was available to bind to the promoter of an inflammatory gene.
Thirdly, Figure 20 shows that L suppressed H2O2 accumulation and inhibited H2O2induced NF-κB activation signals. Briefly, the upstream H2O2 pathway involves a cascade of
proteins. When a signaling protein is phosphorylated, it becomes active. The active protein then
phosphorylates (activates) another protein, and so on. Antibodies can be used to selectively
recognize the phosphorylated (active) form of a protein.
The results showed that before H2O2-stimulation, RAW264.7 cells had almost no
intracellular H2O2 (less than 1% relative intensity), and had low levels of p-IκB (phosphorylatedIκB), p-IKKαβ, p-Akt, p-NIK, oxidized PTEN, and PI3K activity. After H2O2-stimulation,
RAW364.7 cells had dramatically increased H2O2 (100% relative intensity), and had increased
levels of p-IκB, p-IKKαβ, p-Akt, p-NIK, oxidized PTEN, and PI3K activity. H2O2-stimulated
cells that were pretreated with 20 μM L inhibited the changes seen with H2O2-stimulation: L
decreased H2O2 accumulation (13% relative intensity), and decreased levels of p-IκB, p-IKKαβ,
p-Akt, p-NIK, oxidized PTEN, and PI3K activity. Thus, L decreased expression of inflammatory
genes by suppressing intracellular levels of H2O2, which subsequently inhibited the
PI3K/PTEN/Akt and NIK/IKK pathways upstream of the NF-κB pathway.
H2O2

─

+

+

Lutein

─

─

+

rePTEN
oxPTEN
PI3K

p-Akt
p-NIK
p-IKK
Figure 20. Adapted from Kim.64 Lutein inhibits H2O2-induced NF-κB activation mediators.
RAW264.7 cells were treated with H2O2 (200 μM) in the presence of lutein (20 μM). After 10
minutes, the levels of signaling proteins were measured. (Top) Observed protein levels of PTEN
and PI3K using immunoblot analysis. (Bottom) Observed protein levels of phosphorylated Akt,
NIK, and IKK using western blot analysis.

Generally, this study analyzed a widespread set of genes and proteins to get a
comprehensive understanding of the mechanism underlying L’s anti-inflammatory effect. When
these results are combined with the findings of the previous two studies, a signaling pathway can
be assembled to elucidate how L down-regulates the expression of inflammatory genes and
proteins.
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5.1.4 Proposed Mechanism of L’s Anti-Inflammatory Effect
In AMD pathogenesis, upregulation of the inflammatory pathway may contribute to the
degeneration of the macula. Figure 21 proposes an inflammatory pathway that is targeted by L
treatment in LPS-stimulated RAW264.7 cells. Upon stimulation with LPS, extracellular H2O2 is
generated. The extracellular H2O2 then crosses into the cell, leading to the accumulation of
intracellular H2O2. H2O2 inside the cell then activates PI3K and NIK, which subsequently
phosphorylate and activate their corresponding cytokines. Both PI3K and NIK signaling
pathways converge on the phosphorylated activation of IKK, which then phosphorylates IκB.
Phosphorylated IκB is tagged for degradation, allowing NF-κB to dissociate from IκB and
translocate into the nucleus. Once inside the nucleus, NF-κB binds to the promoter region of
inflammatory genes, which increases their transcription. These inflammatory genes are then
translated into proteins, which can go on to promote inflammation in tissues such as those
comprising the macula of the eye.

LPS

Lutein

H2 O2

Extracellular
Intracellular

H2 O2

Lutein

PI3K
PTEN

NIK
Akt

IKK

IκB
Lutein

NF-κB
NF-κB
NF-κB

iNOS
COX-2
VEGF

Nucleus
Figure 21. Adapted from Kim.64 Lutein inhibits the inflammation-related NF-κB pathway. H2O2
and IκB may be potential therapeutic targets for L’s suppression of NF-κB-regulated inﬂammatory
gene expression. Both extracellularly and intracellularly, L scavenges H 2O2. Additionally, L
inhibits degradation of IκB in the cytosol.

Figure 21 pinpoints H2O2 and IκB as potential therapeutic targets for L’s suppression of
NF-κB-regulated inﬂammatory gene expression. Lutein scavenges both extracellular and
intracellular H2O2, such that less H2O2 accumulates in the intracellular space. Less intracellular
H2O2 corresponds to reduced levels of active NIK and PI3K, and increased levels of active PTEN.
Thus, the PI3K/PTEN/Akt and NIK/IKK pathways are inhibited with L treatment. Both pathways
converge on inactive IKK, which does not phosphorylate IκB. Unphosphorylated IκB is not
degraded and remains bound to NF-κB in the cytoplasm. NF-κB is thus sequestered in the
cytoplasm and unable to translocate into the nucleus. Without NF-κB binding to the promoters of
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DNA, there is very low transcription of inflammatory genes. Consequently, there is less
production of proinflammatory proteins such as iNOS, COX-2, and VEGF. Overall, incubating
LPS-stimulated RAW264.7 cells with L was observed to decrease the expression of
proinflammatory molecules that arise from NF-κB signaling.
5.2 Conclusion
Overall, L’s anti-inflammatory effect was suggested to result from the transcriptional
down-regulation of inflammatory molecules. The transcription of inflammatory genes was
directly mediated by the NF-κB pathway, and indirectly mediated by the H2O2-dependent
PI3K/Akt pathway and H2O2-dependent NIK pathway. The studies presented here found that L
may have an anti-inflammatory effect on intraocular inflammation, by inhibiting the NF-κB
dependent signaling pathway upstream of the production of proinflammatory molecules.
In vivo, the amount of L that is available to down-regulate inflammatory molecules may
be dependent on HDL status. Genetic variants in HDL-related genes were previously proposed to
modulate the efficiency by which L/Z undergo uptake and transport into the retina. Increased
HDL-mediated transport of L leads to a greater concentration of L inside retinal cells. There, L
scavenges H2O2 and inhibits IκB degradation, decreasing inflammation of retinal cells.
Suppressing inflammation in the retinal pigment epithelium potentially delays the development of
advanced AMD. The overall HDL-inflammation pathway is potentially one mechanism by which
L reduces risk of advanced AMD.
In the context of personalized nutrition, genetic information that reveals differential
expression of inflammatory genes can be used to create personalized nutritional recommendations
that most effectively delay advanced AMD. Figure 22 depicts how genetic information
concerning gene expression fits into the concept of personalized nutrition. Individuals who are
more susceptible to chronic inflammatory responses involving the iNOS, COX-2, and VEGF
genes may require higher levels of L. Concerning the overall HDL-inflammation pathway,
patients with certain LIPC, CETP, and ABCA1 alleles, as well as chronic expression of NF-κB
dependent inflammatory genes, should likely consume the highest amounts of L/Z.

Genotype

Nutrients

LIPC rs493258
LIPC rs10468017
CETP rs3764261
ABCA1 rs1883025

Dietary L/Z

Gene
Expression

Eye
Disease

iNOS
COX-2
VEGF

Advanced AMD

Figure 22. Personalized nutrition: Profiling the expression of NF-κB dependent proinflammatory
genes. Individuals who are more susceptible to chronic expression of inflammatory genes are at
higher risk for AMD and require higher intakes of L.
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Chapter 6. Future Directions
Current research in the nutrigenomics of AMD has largely focused on epidemiological
studies analyzing the association between L/Z intake and AMD risk. The literature as a whole
consists of a large amount of cross-sectional studies, prospective studies, and randomized clinical
trials, all of which report associations between L/Z in the diet, serum, or supplements, and any
type of AMD.43-45,68-73 Conversely, a moderate amount of research has focused on genotype and
the discovery of genetic variants associated with AMD. An even smaller amount of research has
analyzed the effects of L/Z on the expression of genes involved in AMD. This chapter will
highlight gaps in genotype and gene expression studies, where further investigation is needed.
6.1 Future Directions for Genotype Studies
Future investigation into genotype should focus on employing GWAS studies to identify
variants in other AMD-related genes. In this review, three genetic variants related to HDL status
were identified by GWAS studies. Figure 23 describes other genetic variants, associating L/Z
status with AMD, which have been identified by candidate gene studies. Aside from HDL
status74, there are three groups of genes that may influence L/Z response and AMD risk,
including: 1) genes related to L/Z membrane transport, 2) genes related to carotenoid cleavage,
and 3) genes previously related to age-related maculopathies. Variants in genes related to the
transport of L/Z across cell membranes include CD36, GSTP1, and ApoE.75-79 Variants in genes
related to carotenoid cleavage that may affect retinal uptake of L/Z include BCMO1, BCO2, and
RPE65.60,77-81 Variants in genes previously associated with age-related maculopathies such as
Sorby's fundus dystrophy and Sjorgren-Larsson Syndrome include TIMP355 and ALDH3A278,79,
respectively. These genes should be further examined in order to understand which genetic
variants confer the greatest risk of developing AMD.

CD36

SCARB1

GSTP1
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TIMP3

Carotenoid
Cleavage
Enzymes

ALDH3A2

Age-Related
Maculopathies
RPE65

Figure 23. Genotypes that are important to L/Z status and AMD pathogenesis. These genes were
identified by candidate gene studies and should be further examined in order to understand their
effects on development of AMD.
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However, candidate gene studies have less stringent statistical power than GWAS
studies. Thus, candidate gene studies may reveal false-positive associations. Moving forward, a
GWAS approach should be used to determine if the genetic variants identified by candidate gene
studies truly have a significant impact on the relationship between L/Z and AMD.
At the same time, GWAS studies should also be performed in different ethnic groups
residing in different geographical locations. The genotypes investigated in this review reported
significant associations between HDL-related variants and AMD for Caucasian cohorts in the US.
However, specific genetic backgrounds related to ethnicity may or may not reveal these same
associations. It is therefore necessary to perform GWAS in various racial groups. Doing so will
determine if the results of genotyping, an important part of personalized medicine, can be
generalized and effectively applied to a diverse patient base.
In the context of personalized nutrition, genotyping for other AMD-susceptibility alleles
is important for determining which patients are at the greatest risk for AMD. Figure 24 depicts
how genotyping fits into the concept of personalized nutrition. Variants in genes related to L/Z
membrane transport, carotenoid cleavage enzymes, and known age-related maculopathies may all
influence the body’s response to L/Z. Given that AMD is a complex polygenic disease, data for
all genetic variants related to L/Z response and AMD risk is needed in order to make the most
effective dietary recommendations.
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VEGF
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RPE65,
RPE65, TIMP3,
TIMP3, and
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Figure 24. Personalized nutrition: Further investigation into other AMD-susceptibility alleles.
Genetic variants related to L/Z membrane transport, carotenoid cleavage, and age-related
maculopathies may confer higher risk for AMD.

6.2 Future Directions for Gene Expression Studies
Future investigation into gene expression should focus on in vivo studies, the effects of Z,
and alternative pathways involved in AMD pathogenesis. The particular genes included in this
review were all proinflammatory genes down-regulated by treating LPS-induced RAW264.7 cells
with L. The next step is to test the protective effect of L in vivo using mouse models.
Additionally, the potentially protective effects of Z should be investigated both in vitro
and in vivo. As shown in Figure 25, it has been suggested that Z may up-regulate antioxidant
genes via the Nrf2 pathway.82 According to a study published by Zou in 2014, Z was found to
activate the Nrf2/Keap1 pathway in ARPE-19 cells. Similar to the NF-κB pathway, Z disrupts the
binding between Nrf2 and cytosolic Keap1, freeing Nrf2 to translocate into the nucleus. Nrf2
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binds to DNA and upregulates the transcription of antioxidant phase II enzymes (HO-1, NQO-1,
GCLc, and GCLm). Overall, Z increases the antioxidative capacity of RPE cells by inducing the
protective Nrf2 pathway, inhibiting AMD pathogenesis. Thus, Z’s role in the antioxidant
response and its underlying mechanisms require further investigation.
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82

Figure 25. Adapted from Zou. Zeaxanthin’s (Z) possible antioxidant effect. Z may upregulate
the antioxidant response, protecting against the development of AMD.

In the context of personalized nutrition, genetic information that reveals differential
expression of antioxidant genes can be used to create personalized nutritional recommendations
that most effectively delay AMD. Figure 26 depicts how genetic information concerning gene
expression fits into the concept of personalized nutrition. Individuals with lower expression of
Nrf2-dependent antioxidant genes may require higher levels of Z. Greater understanding of both
L’s effect on inflammatory genes in vivo and Z’s effect on the antioxidant response are needed to
pinpoint the most beneficial level of L/Z intake for individual patients.
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Figure 26. Personalized nutrition: Further investigation into antioxidant genes. Individuals with
low Nrf2-dependent antioxidant responses may be at higher risk of AMD and require higher
intakes of Z.
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Chapter 7. Conclusions
This review compiled primary literature investigating the interactions between dietary
L/Z intake, genetic variation, gene expression, and advanced AMD. First, epidemiological studies
showed that high dietary intake of L/Z may protect relatively younger people in the initial stages
of AMD from progressing to the advanced stage of AMD. Secondly, first-degree relative studies
and twin studies showed that there is a strong genetic basis to AMD. Thirdly, GWAS studies
showed that certain genetic variants in HDL-related genes are associated with AMD risk, possibly
by influencing the transport efficiency of L/Z in retinal cells. Fourthly, in vitro studies showed
that L can protect against AMD by down-regulating proinflammatory genes via the NF-κB
signaling pathway.
A summary of the main findings are presented in Figure 27. A high intake of dietary L
and/or Z was observed to correlate with lower risk of advanced AMD, possibly by protecting
relatively younger persons (60-79 years) with early AMD against progression to the advanced
stage. Certain genetic variants in HDL-associated genes were also suggested to correlate with
lower risk of AMD, possibly by increasing the efficiency of L/Z uptake into retinal cells. Once
inside retinal cells, L was shown to down-regulate the expression of proinflammatory genes and
molecules, possibly inhibiting AMD pathogenesis.
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Figure 27. A summary of the nutrigenomics of AMD. Overall, genotype and gene expression are
key components of the mechanism by which dietary L/Z suppresses the development of advanced
AMD.

Altogether, the research indicates that increasing dietary L/Z intake may be an effective
protective strategy to avoid a large increase in cases of advanced AMD. Since specific genetic
variants confer differential risk to AMD, genomic testing can pinpoint the most effective levels of
dietary intake. Clinically, genetic information should be used to personalize dietary

44

recommendations to delay progression of advanced AMD. To advance the field of eye care, a
personalized nutrition approach should be pursued as the next protective strategy against eye
disease.
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Appendix A
Acronyms and Abbreviations
ABCA1
Akt
ALDH3A2
AMD
ApoE
AREDS
AREDS2
BCMO1
BCO2
BMES
CD36
CETP
ChIP
CNV
COX-2
DNA
DZ
EDCCS
ELISA
EMSA
FFQ
GCLc
GCLm
GSTP1
GWAS
H2O2
HDL
HO-1
HPFS
IKK
iNOS
Keap1
LIPC
LPS
mRNA
MZ
NF-κB
NHANES III
NHS
NIK
NQO-1
Nrf2
NO
O2-

ATP-Binding Cassette Subfamily A Member 1
Protein Kinase B
Aldehyde Dehydrogenase 3 Family Member A2
Age-Related Macular Degeneration
Apoliproprotein E
Age-Related Eye Disease Study
Age-Related Eye Disease Study 2
Beta-Carotene 15,15'-Monooxygenase 1
Beta-Carotene Oxygenase 2
Blue Mountains Eye Study
Cluster of Differentiation 36
Cholesteryl Ester Transfer Protein
Chromatin Immunoprecipitation
Choroidal Neovascularization
Cyclooxygenase 2
Deoxyribonucleic Acid
Dizygotic
Eye Disease Case-Control Study
Enzyme-Linked Immunosorbent Assay
Electrophoretic Gel Mobility Shift Assay
Food-Frequency Questionnaire
Glutamate-Cysteine Ligase Catalytic Subunit
Glutamate-Cysteine Ligase Modifier Subunit
Glutathione S-Transferase Pi 1
Genome-Wide Association Study
Hydrogen Peroxide
High-Density Lipoprotein
Heme Oxygenase 1
Health Professionals Follow-Up Study
Inhibitor of Nuclear Factor Kappa-B Kinase
Inducible Nitric Oxide Synthase
Kelch-Like ECH-Associated Protein 1
Hepatic Lipase
Lipopolysaccharide
Messenger Ribonucleic Acid
Monozygotic
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
Third National Health and Nutrition Examination Survey
Nurses' Health Study
Nuclear Factor-Kappa-B-Inducing Kinase
NAD(P)H Quinone Dehydrogenase 1
Nuclear Factor (Erythroid-2)-Like 2
Nitric Oxide
Superoxide Anion
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1

O2
OH•
OR
PGE2
PI3K
PTEN
RAW264.7
RNA
ROS
RPE
RPE65
RR
RT-PCR
SNP
TIMP3
UK
US
USDA
VEGF
VLDL

Singlet Oxygen
Hydroxyl Radical
Odds Ratio
Prostaglandin E2
Phosphoinositide 3-Kinase
Phosphatase and Tensin Homolog
A Mouse Macrophage Cell Line
Ribonucleic Acid
Reactive Oxygen Species
Retinal Pigment Epithelium
Retinoid Isomerohydrolase
Risk Ratio or Relative Risk
Reverse Transcription-Polymerase Chain Reaction
Single Nucleotide Polymorphism
Tissue-Inhibitor of Metalloproteinase 3
United Kingdom
United States
United States Department of Agriculture
Vascular Endothelial Growth Factor
Very Low-Density Lipoprotein
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